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Main Abbreviations
B.  Biﬁ dobacterium
Bb12  Biﬁ dobacterium animalis ssp. lactis Bb12
Cfu  Colony-forming unit
CI  Conﬁ dence intervals
CRP  C-reactive protein
DC  Dendritic cell
E.  Escherichia
ELISA   Enzyme-linked immunoabsorbent assay 
FACS  Fluorescent-activated cell sorting
GI  Gastrointestinal
IFN  Interferon 
Ig  Immunoglobin
IL   Interleukin
IQR  Interquartile range
L.  Lactobacillus
Lc.  Lactococcus
LGG  Lactobacillus rhamnosus GG
Ln.  Leuconostoc
LPS  Lipopolysaccharide
Mo  Month
PBMC   Peripheral blood mononuclear cell
PCA  Principal component analysis
PLS/DA  Partial least squares discriminant analysis
PJS  Propionibacterium freudenreichii ssp. shermanii JS
RDBPC  Randomized, double-blind, placebo-controlled
S.   Streptococcus
SD  Standard deviation
sIgA  Secretory immunoglobulin A
ssp.  Subspecies
Th  T helper
TLR  Toll-like receptor
TNF  Tumour necrosis factor 
Treg  Regulatory T cell
UPLC/MS Ultra performance liquid chromatography/mass spectrometry 
Wk  Week
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Abstract
Probiotic bacteria have been mostly investigated in the prevention and treatment 
of diﬀ erent gastrointestinal diseases and allergies. Probiotic products, however, are 
usually consumed by the general, healthy population but not much is known on their 
immunomodulatory eﬀ ects in healthy adults. It is not fully clear how probiotics exert 
their beneﬁ cial eﬀ ects on health, but one of the most probable mechanisms of action 
is the modulation of immune responses via the mucosal immune system of the gut. 
The purpose of the present study was to investigate the immunomodulatory properties 
of probiotic strains by systematical screening in primary cell culture using human 
peripheral blood mononuclear cells (PBMC) and to evaluate the eﬀ ects of probiotics 
on the immune system in healthy adults in randomized, double-blind, placebo-
controlled intervention trials. In addition, novel lipidomics proﬁ ling was performed to 
characterize the eﬀ ect of probiotics on lipid-derived mediators.
Probiotic strains from six diﬀ erent genera showed clear diﬀ erences in their ability 
to induce cytokine responses in human PBMC in vitro. Strains from Streptococcus 
and Leuconostoc genera were the most potent inducers of Th1-type cytokines. Strains 
belonging to Biﬁ dobacterium and Propionibacterium genera showed the best anti-
inﬂ ammatory potential by inducing IL-10 production. No combinations of probiotics 
(probiotic multispecies) resulted in enhanced cytokine production compared with 
individual strains (probiotic monospecies), suggesting that diﬀ erent bacteria compete 
with each other during host cell-probiotic interactions. 
The selection of strains for the clinical trials was made based on their anti-
inﬂ ammatory potential. The ability to induce IL-10 (anti-inﬂ ammatory cytokine) or IL-12 
(Th1-type cytokine) production was used to classify the strains as anti-inﬂ ammatory or 
Th1-type favoring strains, respectively. The strains possessing the best anti-inﬂ ammatory 
potential, namely B. lactis ssp. animalis Bb12 (Bb12) and P. freudenreichii ssp. shermanii 
JS (PJS), along with L. rhamnosus GG (LGG) as a well-documented reference probiotic, 
were thus selected for further clinical studies in healthy adults. The results of the in 
vitro setting did not entirely reﬂ ect the in vivo results as the best anti-inﬂ ammatory 
strain was LGG, which induced only moderate IL-10 production in vitro compared with 
Bb12 and PJS strains. During a three-week intervention in healthy adults, serum highly 
sensitive CRP levels showed the lowest levels in the LGG and PJS groups. In the same 
clinical setting, LGG was able to decrease proinﬂ ammatory TNF-α production in ex 
vivo isolated PBMC whereas Bb12 decreased IL-2 production. 
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As LGG seemed to demonstrate the best anti-inﬂ ammatory potential in healthy 
adults, the eﬀ ect of LGG on lipid-derived mediators was investigated. For this purpose, 
global lipidomics proﬁ les in serum were determined. A tendency towards a reduced 
number of inﬂ ammatory lipid-derived mediators, namely lysophosphatidylcholines 
and sphingomyelins, was observed in response to intervention with LGG. 
The eﬀ ect of LGG on the incidence of respiratory infections and gastrointestinal 
symptoms was assessed in a longer, three-month intervention in exercising adults 
participating in a marathon. In this longer intervention, LGG consumption resulted in 
decreased monocyte and serum IL-6 levels at the end of the study period. Serum highly 
sensitive CRP levels were also lower in the LGG group as compared to the controls, 
although the diﬀ erence was not statistically signiﬁ cant. LGG had no eﬀ ect on the 
incidence or duration of respiratory infections in exercising adults. However, LGG was 
able to reduce the duration of gastrointestinal symptoms.
In conclusion, probiotics show a strain-speciﬁ c ability to modulate the release and 
action of inﬂ ammatory mediators in healthy adults. Immunomodulatory eﬀ ects of 
probiotic multispecies should be studied as the eﬀ ects diﬀ er from single strains. As the 
in vitro results did not entirely reﬂ ect the in vivo situation, PBMC in vitro should not be 
used as the only screening method for immunomodulatory eﬀ ects. Instead, the ex vivo 
production of cytokines by PBMC after probiotic intervention could oﬀ er a relatively 
easy and quick screening method for immunomodulatory properties of probiotics. The 
mechanisms of speciﬁ c host-probiotic interactions in the gut resulting in systemic and 
clinical eﬀ ects warrants further investigations.
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1. Introduction
Probiotics are deﬁ ned as live microorganisms that confer a health beneﬁ t on the host 
(FAO/WHO, 2002) and they have been mostly studied in the prevention and treatment 
of gastrointestinal disorders (Lenoir-Wijnkoop et al., 2007). There is evidence that 
probiotics can prevent and reduce the duration diarrhoea in children and adults 
(Sazawal et al., 2006; Szajewska et al., 2001) and reduce the risk of allergy (Ouwehand, 
2007). Probiotic have also been used to prevent or shorten respiratory infections 
(de Vrese et al., 2006; Hatakka et al., 2001). The action mechanisms of probiotics are 
not fully understood, but they are likely to be mediated by the gut mucosal immune 
system. The gut is considered to be the largest immunological organ of the body and 
also the gut microbiota has an important role in the maturation and maintenance of 
the immune system along its protective functions against pathogens (Blaut and Clavel, 
2007; Guarner, 2006). 
The immunomodulatory eﬀ ects of probiotics have not been systematically 
investigated from in vitro screenings to short-term clinical trials and longer 
interventions evaluating the clinical outcome of the probiotic intervention. Although 
probiotics have reduced the respiratory infections in healthy children (Hatakka et 
al., 2001; Weizman et al., 2005) and adults (Olivares et al., 2007), not much is known 
about their immunomodulatory eﬀ ects in healthy adults. The aim of this thesis was 
to systematically screen the cytokine responses induced by probiotics in primary cell 
culture using human peripheral blood mononuclear cells and to evaluate the impact of 
probiotics in the modulation of immune responses of healthy adults in randomized, 
double-blind, placebo controlled clinical intervention studies.
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2. Review of the literature
2.1 Basis for host-probiotic immunomodulatory cross-talk 
2.1.1 Introduction to the immune system
The gastrointestinal tract constitutes a major interface with the external environment. 
The intestinal mucosal surface (around 300 m2) is adapted to the main functions of 
the gut; the digestion of food and absorption of nutrients and the defence against 
microbial pathogens and other hazardous substances. The gut is considered to be the 
largest immunological organ of the human body and the mucosal immune system in 
the gut is often the ﬁ rst line of defence against microbial infections. Immunological 
reactions are divided into two parts by the speciﬁ city and speed of the reaction; innate 
and adaptive responses, although in practice there is extensive interaction between 
them and it is often hard to describe where the innate immunity ends and the adaptive 
immunity starts (for review, see Parkin and Cohen, 2001). The innate immunity provides 
the immediate but non-speciﬁ c host defence and it includes physical, chemical, and 
microbiological barriers as well as many elements of the immune system (neutrophils, 
monocytes, macrophages, complement, cytokines, and acute-phase proteins). The 
adaptive immunity consists of antigen-speciﬁ c reactions through T lymphocytes and 
B lymphocytes. The adaptive immune response is highly speciﬁ c and it develops an 
immunological memory, but its development requires several days or weeks.
2.1.2 Non-immune defence mechanisms
Gut microbiota as a barrier
The human gastrointestinal tract harbours a diverse community of bacteria, and 
molecular analysis has revealed that the gut contains more than 1,000 bacterial species 
(for review, see Egert et al., 2006; Guarner, 2006). Physiological conditions, such as 
acidity and peristalsis, are distinct in diﬀ erent parts of the gut, which is reﬂ ected in 
the distribution of the bacteria. The concentrations of bacteria in the stomach and the 
duodenum is approximately 103 cfu/ml, increasing to 104-108 cfu/ml in the jejunum 
and the ileum and reaching the highest concentration of up to 109-1012 cfu/ml in the 
colon (Blaut and Clavel, 2007). Microbiota is established at birth and its composition 
and development depends on the mode of delivery (Grönlund et al., 1999; Huurre et al., 
2007) and feeding (Favier et al., 2002). During the ﬁ rst months of life, the microbiota 
changes and becomes more complex, reaching a composition similar to adults by the 
age of one to two (Palmer et al., 2007). There is a high inter-individual variability, but 
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the microbiota stays relatively stable over time (Zoetendal et al., 1998) although disease 
(Tlaskalova-Hogenova et al., 2004), antibiotic treatments (Jernberg et al., 2007) and diet 
(O’Keefe, 2008) can alter it. The gut microbiota possesses several metabolic functions 
as it ferments non-digestible dietary residue, induces the production of short chain 
fatty acids to retain energy and produces vitamin K (Guarner, 2006). Furthermore, it 
has trophic functions in controlling epithelial cell proliferation and diﬀ erentiation. 
The gut microbiota has an important function in the maturation and maintenance 
of the immune system and it also provides protection against microbial pathogens 
(the barrier eﬀ ect) (Guarner, 2006). The commensal bacteria that have colonized the 
gut restrict the growth of the exogenous or opportunistic pathogenic bacteria. The 
barrier eﬀ ect is based on the ability of the commensal bacteria to secrete antimicrobial 
substances, such as bacteriocins that inhibit the growth of bacteria as well as on the 
competition of nutrients and attachment to the epithelia. 
Mucosal barrier 
The mucosal surface of the gastrointestinal tract is the largest body surface that is 
in contact with the external environment (approximately 300 m2). The physical and 
chemical barriers created by the intestinal epithelium protect the host from pathogens. 
The intestinal epithelial cells provide a physical barrier against pathogens, and the 
integrity of the epithelial layer is maintained by tight junctions, adherence junctions and 
desmosomes (for review, see Acheson and Luccioli, 2004). Transcellular and paracellular 
ﬂ uxes are tightly controlled by membrane pumps, ion channels and tight junctions, 
adapting the permeability according to physiological needs (Baumgart and Dignass, 
2002). Furthermore, being covered by specialized mucus-producing cells, antimicrobial 
peptides such as defensins, and other antimicrobial molecules, such as lysozyme, 
which together with commensal microbiota provide defence against pathogens, the 
intestinal epithelium also provides a chemical barrier against pathogens (for review, 
see Lievin-Le Moal and Servin, 2006). Disturbance at any level, but particularly bacterial 
translocation due to increased permeability and breakdown of oral tolerance resulting 
from compromised epithelial and T cell interaction, can cause inﬂ ammation and tissue 
damage (Baumgart and Dignass, 2002).
2.1.3 Intestinal epithelium and recognition of microorganisms
The intestinal epithelium is rapidly and constantly renewed by epithelial stem cell 
population. The stem cell population diﬀ erentiates into multiple intestinal epithelial cell 
types specialized in diﬀ erent functions (goblet cells, enteroendocrine cells, enterocytes, 
Paneth cells and M cells). These epithelial cells serve as a physical barrier between the 
luminal contents (food antigens and commensal microbiota) and the complex mucosal 
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immune system (for review, see McCracken and Lorenz, 2001). They also play a crucial 
role in signalling and mediating host innate and adaptive immune responses. Activation 
of the host defence mechanisms is based on the rapid recognition of speciﬁ c structural 
components of microorganisms (both commensal and pathogenic microorganisms), 
known as pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide 
(LPS), lipoprotein, peptidoglycan, lipoteichoic acid, ﬂ agelline and CpG-containing 
(unmethylated) DNA (for review, see Alexopoulou and Kontoyiannis, 2005; Sansonetti, 
2004; Winkler et al., 2007). These components are recognized by pattern-recognition 
receptors, of which the best known are the Toll-like receptors (TLRs) and nucleotide-
binding oligomerisation domain proteins (NODs) (for review, see Uematsu and Akira, 
2008; Underhill, 2007). TLR family includes at least 12 proteins that recognizes microbe-
derived ligands. For example, TLR2 recognizes lipoproteins and lipid-modiﬁ ed sugars, 
TLR4 recognizes LPS whereas TLR9 recognizes CpG motifs in bacterial DNA (for 
review, see Uematsu and Akira, 2008). NOD receptors are cytoplasmic receptors that 
recognize peptidoglycan from bacterial cell walls (for review, see Underhill, 2007). In 
general, the stimulation of TLRs or NODs by PAMPs results to the activation of adaptor 
proteins, which initiates a signalling cascade involving several kinases. Eventually, the 
signals are transmitted via transcription factors such as NF-κB, which then initiate the 
transcription of genes leading to the synthesis of immunomodulatory molecules such 
as cytokines, chemokines and other inﬂ ammatory eﬀ ector molecules.
2.1.4 Communication within the immune system 
In order for immune cells to work eﬀ ectively, they need to be recruited to the site of 
inﬂ ammation and become appropriately activated (for review, see Parkin and Cohen, 
2001). This is achieved by the interaction of cellular receptors signalling internally 
to the nucleus as described above, and external factors, such as cytokines, which are 
able to bind the receptors, and also with other adhesion molecules. A summary of the 
mediators within the immune system is presented in Table 1. 
Adhesion molecules 
Adhesion molecules are cell surface molecules involved in cell-to-cell interactions 
(Muzio et al., 2000). Their main function is in facilitating cellular functions, such as 
directing cell migration, phagocytosis, and cellular cytotoxicity. The main adhesion 
molecules include the intercellular adhesion molecules (ICAMs), integrins, selectins, 
and cadherins (calcium-dependent adherins). In addition to the molecules on 
leukocytes, and vascular endothelium, there are also tissue-speciﬁ c adhesion molecules 
called addresins.
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Cytokines
Cytokines are small proteins that are released by immune cells as well as by many other 
cell types (Vilcek, 2003). Cytokines alter the behaviour of the cell in an autocrine or 
paracrine fashion, i.e. by aﬀ ecting the same cell that produced the cytokine or another 
cell that is close the cytokine releasing cell. Each cytokine may have multiple activities 
on diﬀ erent cell types. Cytokines act by binding to their speciﬁ c receptors on the cell 
surface and by inducing changes in the growth, development, or activity of the target 
cell. Cytokines produced by leukocytes and having eﬀ ects mainly on other white cells 
are termed interleukins (ILs). Cytokines that have chemoattractant activity are called 
chemokines. Colony-stimulating factors (CSFs) function as important diﬀ erentiation 
and proliferation factors for stem cells. Interferons (IFNs) inhibit the replication of 
viruses and regulate the activation of the immune system.
Cytokine production patterns are used to divide T helper cell (Th) responses to 
diﬀ erent classes. Th1-type cells produce IL-2 and IFN-γ and promote cell-mediated 
immunity (Kidd, 2003). Th2-type cells produce IL-4, IL-5, IL-6 and IL-13 and activate the 
antibody-mediated immune response as well as eosinophils and mast cells (Kidd, 2003). 
Th3-type cells downregulate the inﬂ ammatory response through TGF-β production 
and Tr1 cells balance the immune responses through IL-10 production (Izcue and 
Powrie, 2008; Taylor et al., 2006; Wu et al., 2007). Cytokines can also be classiﬁ ed 
according to their pro- or anti-inﬂ ammatory properties. Inﬂ ammatory cytokines 
include TNF-α (Bertazza and Mocellin, 2008), IL-1α/β (Barksby et al., 2007), IL-6 
(Gabay, 2006) and IFN-γ (Schoenborn and Wilson, 2007) whereas IL-10 is considered 
to be an anti-inﬂ ammatory or regulatory cytokine (Couper et al., 2008). TNF-α, IL-1 
and IL-6 also mediate the systemic eﬀ ects of inﬂ ammation, such as fever, weight loss, 
and hepatic acute-phase protein synthesis. The production of appropriate amounts of 
these cytokines is important in response to inﬂ ammation. However, inappropriate or 
excessive production of cytokines can be dangerous, and these cytokines, particularly 
TNF-α, are implicated in causing some of the pathological responses that occur in 
acute and chronic inﬂ ammatory conditions. 
TNF-α is a proinﬂ ammatory cytokine that activates immune system and is involveld 
in the local inﬂ ammation (Bertazza and Mocellin, 2008). It is produced by professional 
immune cells like macrophages, NK cells and T cells, but also non-immune cells like 
epithelial cells are able to induce TNF-α. IL-1β is mainly produced by macrophages 
and epithelial cells and it is involved in T cell and macrophage activation (Barksby et 
al., 2007). IL-6 is produced by T cells, macrophages and endothelial cells and is involved 
in T- and B-cell growth and and diﬀ erentiation, acute phase response and fever (Gabay, 
2006). 
IL-2, produced by T cells, is called as a T cell growth factor and it induces T cell 
proliferation. IL-12 induces the production of IFN-γ and diﬀ erentiates Th cells to 
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Th1-type cells and forms a link between innate and adaptive immunity (Trinchieri, 
2003). Dendritic cells and phagocytes produce IL-12 during infection in response to 
pathogens and it also activates NK cells (Trinchieri, 2003). IFN-γ, produced by T cells 
and NK cells, possesses antiviral activity and it activates macrophages and suppresses 
Th2 responses (Schoenborn and Wilson, 2007).
IL-4 and IL-5 are produced by T cells and mast cells. IL-4 activates B cells, is involved 
in IgE switch and suppresses Th1 cells. IL-5 is induces the growth and diﬀ erentiation 
of eosinophils. IL-10 is an anti-inﬂ ammatory cytokine and it can be produced by many 
types of cells (Couper et al., 2008). During infection it inhibits the activity of Th1 cells, 
NK cells, and macrophages, all of which are required for optimal pathogen clearance 
but also contribute to tissue damage (Couper et al., 2008). 
Chemokines
Chemokines are particular members of the cytokine family that have a key role in 
regulating leukocyte migration (Ono et al., 2003). They have substantial chemotactic 
function (inducing the directional movement of cells). Chemokines are produced by 
most cells on stimulation with proinﬂ ammatory cytokines or bacterial products and 
chemokine receptors are found on all leukocytes. Inﬂ ammatory chemokines control 
leukocyte traﬃ  c in acute inﬂ ammation or infection (Bono et al., 2007). Homeostatic 
chemokines in turn regulate leukocyte haematopoiesis and leukocyte migration 
to spleen and lymph nodes (Bono et al., 2007). CXCL8, interleukin 8 (IL-8), has a 
chemotactic role in attracting neutrophils into the site of inﬂ ammation or infection 
(Kobayashi, 2008). CXCL10, interferon-inducible protein 10 (IP-10), as well CCL2, 
monocyte chemotactic protein-1 (MCP-1), play a role in the recruitment of monocytes 
to sites of injury and infection (Ono et al., 2003).
Acute phase proteins 
A systemic acute-phase response may develop during inﬂ ammation or infection (for 
review, see Beutler, 2004; Gabay and Kushner, 1999; Volanakis, 2001). Most infections 
trigger several secondary eﬀ ects throughout the host. These include the development 
of fever, a fall in plasma iron levels, and the synthesis of acute-phase proteins. Although 
most APRs are synthesized by hepatocytes in response to the action of peripheral 
cytokines (IL-6, TNF-α and IL-1β), some are produced by other cell types, including 
monocytes, endothelial cells, ﬁ broblasts and adipocytes. The major acute-phase 
proteins in humans are serum amyloid A (SAA) and C-reactive protein (CRP). Acute-
phase proteins have a wide range of activities that contribute to host defence: they 
can bind and neutralize inﬂ ammatory agents, such as pathogenic microbes, help to 
minimize the extent of local tissue damage, as well as participate in tissue repair and 
regeneration. Erythrocyte sedimentation rate (ESR) is used as a non-speciﬁ c measure 
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of inﬂ ammation and as a “sickness index”, but it is limited by its low sensitivity and 
speciﬁ city (Brigden, 1998). The high-sensitivity CRP is considered to be a very sensitive 
marker of inﬂ ammation. Low-grade inﬂ ammation, characterised by increased plasma 
CRP concentrations and increased systemic levels of certain cytokines are nowadays 
considered to be risk factors for various chronic diseases, such as atherosclerosis and 
metabolic syndrome (Chen, 2006). 
Lipid-derived mediators
The inﬂ ammatory response consists of immunological and non-immunological 
reactions. Non-immunological reactions are induced by the release of lipid-derived 
compounds from injured tissues and migrating cells. Many of the changes in lipid-
derived compounds during infection/inﬂ ammation help to protect the host from 
harmful eﬀ ects of inﬂ ammatory substances (for review, see Khovidhunkit et al., 2004). 
Eicosanoids are derived from cell membrane phospholipids by the activation of 
phospholipase A2 and the release of arachidonic acid (Khanapure et al., 2007). The 
arachidonic acid is subsequently transformed by cyclooxygenase and lipoxygenase 
pathways to prostaglandins, thromboxane and leukotrienes collectively termed 
eicosanoids. Eicosanoid production is considerably increased during inﬂ ammation. 
The main eicosanoids are prostaglandins (PGD2, PGE2, PGF2α), prostacyclin (PGI2), 
thromboxane A2 (TXA2) and leukotrienes (LTs). Prostaglandins are involved in 
the regulation of circulation. In addition to its proinﬂ ammatory eﬀ ects, PGE2 has 
cytoprotective functions e.g. in the gastric mucosa. Prostaglandins and leukotrienes 
also contribute to the generation of the signs and symptoms of inﬂ ammation. 
Also lipid-derived compounds have been related to diﬀ erent diseases. For 
example phospholipids, such as lysophosphatidylcholine, have been associated with 
atherosclerosis (Kougias et al., 2006) as well as inﬂ ammatory bowel disease (Haapamäki 
et al., 1999; Minami et al., 1994), impaired mucosal barrier function and increased gut 
permeability (Karlqvist et al., 1986; Otamiri et al., 1986; Sawai et al., 2002; Tagesson et 
al., 1985). Sphingolipids and lipids of the sphingomyelin/ceramide pathway in high 
concentrations have been associated with inﬂ ammatory processes in the development 
of atherosclerosis (Bismuth et al., 2008) and inﬂ ammatory bowel disease (Homaidan et 
al., 2002; Sakata et al., 2007).
Reactive oxygen species, reactive nitrogen species and degradative enzymes
Major phagocytic cells (neutrophils, macrophages, monocytes) engulf pathogenic 
microbes and use diﬀ erent metabolites for killing microbes (for review, see Beutler, 
2004; Chaplin, 2006; Parkin and Cohen, 2001; Won and Singh, 2006). The oxygen-
dependent response or respiratory burst involves the sequential reduction of oxygen 
by an NADPH oxidase leading to production of oxygen metabolites, such as hydrogen 
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peroxide, hydroxyl radicals, superoxide and singlet oxygen. The oxygen-independent 
response uses the degradative enzymes, myeloperoxidase and lysozyme, on microbe 
destruction. Nitric oxide takes part in many physiological processes; besides its role in 
the regulation of circulation and inﬂ ammation, it also acts as an eﬀ ector molecule in 
innate immune responses and contributes to host defence (for review, see Tripathi et 
al., 2007).
Amines
Histamine is an essential biological amine in inﬂ ammation and allergy (Xie and He, 
2005). In addition to its role in acute inﬂ ammatory and immediate hypersensitivity 
responses, it has been demonstrated to aﬀ ect chronic inﬂ ammation and regulate several 
essential events in the immune response (Jutel et al., 2006). Histamine is mostly found 
in the lungs, skin and the gastrointestinal tract. It is stored in mast cells and basophils 
from which it is released by the action of complement or IgE. Serotonin (5-HT) is found 
in the gastrointestinal tract, platelets and central nervous system. 5-HT is known to 
increase gastrointestinal motility, to contract bronchi, uterus and arteries, and its role 
in inﬂ ammatory and immunological responses has recently been of interest (Cloez-
Tayarani and Changeux, 2007).
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Mediator Major functions
Adhesion molecules Integrins, selectins, 
cadherins, addresins
Facilitation of 
cell-to-cell interactions
Cytokines
Tumour necrosis 
factors
TNF-α, TNF-β Activation of many cells, induction of 
apoptosis, proinfl ammatory function
Interleukins IL-1α/β, IL-2, IL-4, IL-5, 
IL-6, IL-10, IL-12, IL-13
Regulation of immune cell function 
and activation
Transforming growth factor TGF-β Inhibition of cell growth, anti-
infl ammatory, induction of IgA 
secretion
Interferons IFN-α, -β, -λ, -γ Antiviral activity, inhibition of tumour 
cell growth, activation of cells
Chemokines CCL2, -3, -4, -5
 CXCL8, -10 etc.
Chemotaxis and activation of 
immune cells
Colony-stimulating factors GM-CSF, G-CSF, IL-3 Growth and differentiation 
of haematopoietic cells
Growth factors EPO, TPO, EGF, FGF, PDGF Growth and differentiation 
of cells
Acute-phase proteins CRP, serum amyloid A, 
fi brinogen
Participation in host defence, 
neutralisation of infl ammatory 
agents, inhibition of local tissue 
damage
Lipid-derived mediators
Eicosanoids Prostaglandins, prostacyclin, 
thromboxane, leukotrienes
Infl ammatory mediators, 
some members have 
cytoprotective functions
Phospholipids Phosphatidylcholine, 
lysophosphatidylcholine
Regulation of cell function, 
involved in oxidative metabolism, 
infl ammatory mediators
Sphingolipids Sphingomyelin, 
ceramide
Regulation of many biological 
processes, part of cell membranes, 
immunomodulation
Reactive oxygen and nitrogen 
species
Hydrogen peroxide, hydroxyl 
radicals, superoxide, singlet oxygen, 
nitric oxide
Participation in innate immune 
response, killing of microbes
Enzymes Lysozyme, myeloperoxidase Participation in innate immune 
response, killing of microbes
Amines Histamine, serotonine Infl ammatory reactions, 
immunomodulation
Table 1. Summary of main mediators within the immune system.
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2.1.5 Mucosal immunity
The mucosal immunity serves as the ﬁ rst line of defence that reduces the need for systemic 
immunity, which is principally “proinﬂ ammatory”. The mucosal immune system can be 
functionally and physically divided into inductive sites (the Peyer’s patches) and eﬀ ector 
sites (the lamina propria) (for review, see Cummings et al., 2004; McCracken and Lorenz, 
2001). In the inductive sites, the mucosa-associated lymphoid tissue (MALT) is covered 
with follicle-associated epithelium (FAE) which contains M cells. These specialized cells 
eﬀ ectively transport microorganism as well as foreign antigens from the gut lumen into 
the underlying organized lymphoid tissue containing antigen-presenting cells (APC) 
(macrophages and dendritic cells) and mucosal T and B cells. Microorganisms/antigens 
are presented to T and B cells after intracellular processing. In addition, antigens may 
be taken up and presented by intra- or subepithelial dendritic cells directly as they may 
penetrate epithelium by their cellular extensions or processes. Activated T cells release 
cytokines which may diﬀ erentiate B cells to antibody (IgA, IgM) producing plasma 
cells. Most activated B cells migrate to mesenteric lymph nodes where they are further 
stimulated, followed by homing into distant mucosal eﬀ ector sites, particularly the 
intestinal lamina propria where they ﬁ nally develop to antibody producing plasma cells. 
Subsequently, antibody-mediated mucosal defence inhibits the surface colonization of 
the pathogens. 
Another important role of the mucosal immune system in addition to preventing 
the entry of pathogens through the gastrointestinal tract is to discriminate pathogenic 
microorganisms from harmless food antigens and commensal bacteria (Dubois et al., 
2005). Every year, approximately 1,000 kilograms of food pass the human gut containing 
roughly two kilograms of commensal bacteria. To this end, to avoid local and peripheral 
hypersensitivity, immunosuppressive mechanisms inducing “oral tolerance” have 
developed. (Dubois et al., 2005). 
2.1.6 Innate immune response
The innate immune response provides fast and unspeciﬁ c host defence (for review, see 
Parkin and Cohen, 2001; Tosi, 2005). Inﬂ ammation is the body’s immediate response to 
diﬀ erent inﬂ ammatory stimuli or injury and is an integral part of the innate immune 
response. Inﬂ ammation protects the host from threatening agents or events and their 
ultimate purpose is to neutralize the original cause (pathogen, injury). Recognition 
of a threatening agent or event initiates an inﬂ ammatory response in the epithelial 
surfaces. During the very early stages of inﬂ ammation or tissue damage, a release of 
cytokines from the activated macrophages occurs. These cytokines recruit leukocytes 
to the inﬂ ammation site. Cytokines released by phagocytes (macrophages, monocytes, 
neutrophils) also activate the acute-phase response. Chemokines released by phagocytes 
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recruit more cells, such as leukocytes, to the inﬂ ammatory site. After entering tissues, 
many pathogens are killed by phagocytes or natural killer (NK) cells. The ingestion and 
killing of pathogens is more eﬀ ective if the microbe is ﬁ rst opsonised with speciﬁ c 
antibody or complement which is a system of plasma proteins that interacts with 
pathogens to mark them for destruction by phagocytes.
2.1.7 Adaptive immune response
Non-speciﬁ c responses of innate immunity are necessary for the adaptive immunity 
to be initiated, and several lymphocyte subpopulations and antibodies take part in 
regulating innate and adaptive immunity. The adaptive immune response is speciﬁ c 
with immunological memory, but takes several days or weeks to develop (for review, see 
Parkin and Cohen, 2001). T and B cell responses are initiated in peripheral lymphoid 
organs by activated antigen-presenting cells, after which the eﬀ ector responses take 
place. Cytokines produced in the early phases of an inﬂ ammation inﬂ uence the 
functional diﬀ erentiation of T cells into T helper (Th1, Th2, Th3), cytotoxic T cells or 
regulatory T (Tr1) cells (Izcue and Powrie, 2008; Kidd, 2003). Activated T cells leave the 
lymphoid tissue and home in the inﬂ ammatory site. Th1 and cytotoxic T cells promote 
cell-mediated immunity. Th1 cells coordinate the host response to intracellular 
pathogens and have a central role in phagocyte activation by promoting microbial 
killing. They must be tightly regulated to avoid tissue damage. Cytotoxic T cells are 
selective killers of microbe-infected target cells expressing a speciﬁ c antigen. Th2 cells 
promote humoral immunity leading to activation of B cells (plasma cells) and the 
release of antibodies (immunoglobulins, Ig) into blood and tissue ﬂ uids. IgG and IgA 
neutralize bacteria, bacterial toxins and the infectivity of viruses whereas IgE-mediated 
activation of accessory cells (mast cells, basophils, eosinophils) has an important role 
in parasite infections and also in allergy. Regulatory T cells (Th3 and Tr1) balance the 
immune responses and limit the inﬂ ammatory response. Resolution of inﬂ ammation 
is accompanied by the death of most of the eﬀ ector cells, generation of memory cells as 
well as repair of the local tissue damage.
 
2.1.8 Importance of regulated immune and inﬂ ammatory responses 
Inﬂ ammation is a general term for the local accumulation of ﬂ uid, plasma proteins 
and white blood cells which is initiated by a threatening agent or event. Classical 
signs of acute inﬂ ammation include redness (rubor), heat (calor), swelling (tumor) 
and pain (dolor), as well as loss of function (functio laesa). Acute inﬂ ammation is a 
limited beneﬁ cial response, especially during infectious challenges, whereas chronic 
inﬂ ammation is a persistent phenomenon that can lead to tissue damage. Chronic 
– 25 –
inﬂ ammation is not characterized by the classic signs of acute inﬂ ammation listed 
above. Instead, chronically inﬂ amed tissue is characterized by the inﬁ ltration of 
mononuclear immune cells (monocytes, macrophages, lymphocytes and plasma cells), 
tissue destruction, and attempts of healing, which include angiogenesis and ﬁ brosis. 
Regulated inﬂ ammatory responses are therefore essential for the overall health and 
maintenance of homeostasis (Figure 1). 
Immune responses may also be misdirected or overreactive as in the case of 
autoimmune and atopic diseases (Chaplin, 2006). In autoimmune diseases, such as 
rheumatoid arthritis and type 1 diabetes, the body overreacts to self-antigens with Th1-
type immune response patterns. In atopic diseases, the immune response is skewed 
towards a Th2-type response leading to hypersensitivity to normally innocuous 
environmental antigens. The body can also remain nonresponsive in certain situations, 
giving for instance tumours an opportunity to develop.
Figure 1. Balanced and suﬃ  cient immune response is essential for the resolution 
and repair of inﬂ ammation as well as maintenance of homeostasis and health. Both 
excessive and inadequate immune responses can lead to the development of a disease.
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2.1.9 Factors aﬀ ecting the immune system
The immune system is inﬂ uenced by genetic and environmental factors (for review, see 
Albers et al., 2005; Calder and Kew, 2002; Cummings et al., 2004). Factors contributing to 
the immune function include genes, age, gender, acute and chronic exercise, smoking, 
alcohol consumption, obesity, pregnancy, hormonal status and commensal microbiota 
in the gut. Due to the diversity of these factors, there is wide inter-individual variation 
in immune responses (Yaqoob et al., 1999).
Age
Immune function changes with age. The immune system of a newborn child is 
still developing, and the adaptive immune system is immature due to low antigen 
exposure. Postnatally, intestinal microbes provide the developing gut with stimuli that 
are necessary for healthy maturation of the intestinal immune system (Rautava and 
Walker, 2007). Nutrition plays a role in the maturation of the immune system as well 
(Calder et al., 2006). In normal healthy adults, the nature of the immune response varies 
according to the inﬂ ammatory or infectious agent. There may be small increases or 
decreases in diﬀ erent markers of immune function over time, but a change in one or 
two immune functions is probably not clinically important because other components 
may compensate for the change. Aging is associated with changes in immune 
function (for review, see Pawelec, 2006); Th1 responses, lymphocyte proliferation and 
immunoglobulin levels decrease with age and the increase in Th2 responses and 
prostaglandin E2 levels result in decreased infection resistance.
Exercise
Heavy exercise causes a temporary depression of immune function and periods of 
intense training lasting over one week as well as exercise competitions may lead to 
a longer lasting immune dysfunction (for review, see Gleeson, 2007). This can lead to 
an increased risk of upper respiratory tract infections in heavily exercising athletes 
(Gleeson, 2000). Strenuous exercise is also known to cause many gastrointestinal 
symptoms, such as nausea, vomiting, diarrhoea and heartburn (Peters et al., 2001; Simons 
and Kennedy, 2004). Moderate regular training is associated with reduced incidence 
of infections compared with a sedentary state. Furthermore, exercise mediates several 
other health beneﬁ ts (for review, see Gleeson, 2007). 
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2.2 Immunomodulatory effects of probiotics 
2.2.1 Overview of probiotics 
Probiotics are deﬁ ned as live microorganisms which, when administered in adequate 
amounts, confer a health beneﬁ t on the host (FAO/WHO, 2002). The most commonly 
used probiotics are lactobacilli and biﬁ dobacteria, but also other strains have been used 
as a probiotics (Table 2). Reported possible health eﬀ ects in human intervention trials 
include amelioration of acute diarrhoea in children, reduction of the risk of antibiotic-
associated gastrointestinal symptoms, relief of milk allergy/atopic dermatitis in infants, 
reduction in the risk of atopic diseases and respiratory infections, relief of irritable 
bowel syndrome and rheumatoid arthritis symptoms, suppression of Helicobacter pylori 
and modulation of the immune response (for review, see Lenoir-Wijnkoop et al., 2007). 
The ways in which probiotic bacteria elicit their health eﬀ ects are not fully understood. 
One of the most probable means is the immunomodulatory eﬀ ect mediated by the gut 
mucosal immune system which is reﬂ ected on the systemic level. Immunomodulative 
eﬀ ects of probiotics have been investigated in allergy (for review, see Boyle and Tang, 
2006; Ouwehand, 2007) and inﬂ ammatory diseases, such as inﬂ ammatory bowel disease 
(for review, see Ewaschuk and Dieleman, 2006; Limdi et al., 2006). Probiotics are, however, 
usually consumed by the general, healthy population but not much is known about 
the nature of the eﬀ ects, if any, they have on the immune function in normal healthy 
subjects. The need to study the health eﬀ ects of probiotics also in the healthy population 
is evident, and only a few randomised, double-blind, placebo-controlled studied have 
thus far addressed this question. 
Lactobacillus Bifi dobacterium Other
L. rhamnosus B. bifi dum Streptococcus thermophilus
L. casei B. lactis Lactococcus
L. acidophilus B. longum Propionibacterium
L. plantarum B. breve Saccharomyces
L. johnsonii B. animalis Escherichia coli ssp.
L. reuteri Enterococci
L. salivarius Bacillus
L. helveticus
L. fermentum
L. bulgaricus
Table 2. The most commonly used probiotics.
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2.2.2  Possible mechanisms for host-probiotic immunomodulatory 
cross-talk
It is known that probiotics are able to modulate many aspects of the non-immune 
defence. The possible mechanisms for host-probiotic interaction have mainly been 
studied in animal and in vitro models. Lactobacillus strains have been shown to modulate 
the composition and metabolism of commensal microbiota (Kuisma et al., 2003; Siigur 
et al., 1996) and to compete with the pathogens. They can inhibit pathogen adhesion 
by competitive exclusion, as shown by diﬀ erent Lactobacillus, Biﬁ dobacterium and 
Propionibacterium strains in in vitro models (Collado et al., 2006; Collado et al., 2007) and 
by inducing intestinal mucin production, as shown by Lactobacillus, Biﬁ dobacterium and 
Streptococcus strains in rat and in vitro models (Caballero-Franco et al., 2007; Mack et al., 
2003; Mack et al., 1999). In addition, lactobacilli and biﬁ dobacteria are able to produce 
antimicrobial agents, such as organic acids, hydrogen peroxide, diacetyl, short chain 
fatty acids and bacteriocins, against pathogens (for review, see Servin, 2004). Probiotics, 
such as VSL#3 probiotic mixture, E. coli Nissle and L. rhamnosus GG, can also strengthen 
the mucosal barrier function in mice and in vitro models (Johnson-Henry et al., 2008; 
Madsen et al., 2001; Ukena et al., 2007). Strengthening of the mucosal barrier function 
may be due to normalization of gut permeability (Isolauri et al., 1993a; Isolauri et al., 
1993b), regeneration of epithelial cells (Banasaz et al., 2002) and strengthening of tight 
junctions (Zyrek et al., 2007), as shown for L. rhamnosus GG in rat model and for E. coli 
Nissle in in vitro model. 
Probiotics are likely to mediate their health eﬀ ects through the gut mucosal immune 
system and thereby modulate innate and adaptive immune responses (Schiﬀ rin and 
Blum, 2002). Probiotics are recognised by TLRs (Foligne et al., 2007; Miettinen et al., 
1998; Vinderola et al., 2005) in the gut epithelial cells and/or antigen-presenting cells 
and they thus induce a cascade of immunological events. Probiotics, such as Lactobacillus 
and Biﬁ dobacterium strains, may therefore modulate inﬂ ammatory processes through 
epithelial cells as shown in an in vitro model (O’Hara et al., 2006) and through underlying 
professional antigen-presenting cells, such as macrophages and dendritic cells. It has 
been shown that macrophages in the Peyer’s patches of mice can ingest lactobacilli in 
a strain dependent manner (Sun et al., 2007). Probiotics may then further modulate 
the cytokine expression patterns of dendritic cells and macrophages, as shown by 
L. rhamnosus GG strain in an in vitro model (Miettinen et al., 2000; Veckman et al., 2003; 
Veckman et al., 2004). These probiotic-primed antigen-presenting cells can in turn 
modulate the diﬀ erentiation of naïve T cells into diﬀ erent T cell populations depending 
on the types of cytokines produced, as in the case of diﬀ erent Lactobacillus strains (Braat 
et al., 2004; Smits et al., 2005). Cytotoxic T cells and Th1 cells promote the cell-mediated 
immune response and induce phagocytosis. Lactobacillus and Biﬁ dobacterium strains 
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have increased phagocytosis (Arunachalam et al., 2000; Olivares et al., 2006a; Roessler et 
al., 2008) as well as the number of cytotoxic T cells in clinical studies in adults (de Vrese 
et al., 2005b; Meyer et al., 2006). In allergic children, the induction of Th1-type immune 
response and low-grade inﬂ ammation by L. rhamnosus GG has been proposed as an 
action mechanism for the prevention of atopic diseases (Marschan et al., 2008; Viljanen 
et al., 2005b). Th2 cells promote antibody-mediated immune response and probiotics 
have been shown to modulate this response. Biﬁ dobacterium and Lactobacillus strains 
have regulated the synthesis of IgA by mucosal lymphoid cells (Leblanc et al., 2004; 
Park et al., 2002). L. rhamnosus GG has increased antibody-secreting cells in patients 
with Crohn’s disease (Malin et al., 1996) and in children (Kaila et al., 1992; Majamaa 
et al., 1995) and also faecal IgA in allergic (Viljanen et al., 2005a) and Biﬁ dobacteria in 
healthy children (Fukushima et al., 1998). Moreover, a combination of L. rhamnosus GG 
and B. animalis ssp. lactis Bb12 has increased the IgA-secreting cells in infants (Rautava 
et al., 2006). L. rhamnosus GG and B. animalis ssp. lactis Bb12 have also modulated the 
formation of regulatory T cells in a murine model (Feleszko et al., 2007) which in 
turn control inﬂ ammatory and immune responses. Probiotics can also modulate the 
production of inﬂ ammatory mediators other than cytokines. Induction of low-level 
synthesis of NO may be involved in the protective actions of Lactobacillus strains in 
the gastrointestinal tract as shown in rat and in vitro models (Korhonen et al., 2001; 
Sobko et al., 2006). Additionally, probiotics may modulate the functional responses 
of mast cells from degranulation and histamine production to cytokine production. 
Supplementation with L. paracasei has attenuated the onset of atopic dermatitis-like 
symptoms, accompanied by less mast cell inﬁ ltration and lower plasma IgE levels in a 
mice model (Wakabayashi et al., 2008). Milk fermentation products of L. helveticus have 
increased the number of mucosal mast cells and goblet cells in a mice model, which 
could mean an improved state of mucosal surveillance at sites of infection (Vinderola et 
al., 2007). Events regulating host-probiotic cross-talk in the gut and intestinal mucosa 
is presented in Figure 2.
In summary, probiotics are likely to mediate their health eﬀ ects through 
the gut mucosal immune system and thereby modulate innate and 
adaptive immune responses. Probiotics can also strengthen non-immune 
defence systems. The mechanisms of action of probiotics have been mainly 
investigated in experimental studies. Some studies performed in diﬀ erent 
disease groups, such as in allergy, have addressed the action mechanisms 
of probiotics. 
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Figure 2. A schematic presentation of the host-probiotic cross-talk in the intestinal 
mucosa and the possible action mechanisms of probiotics.
– 31 –
– 32 –
2.2.3 Immunomodulatory properties in human primary cell cultures
In vitro studies are studies in which isolated cells are exposed directly to diﬀ erent 
stimulants, such as probiotics or pathogens, in a culture. This allows the investigation 
of immunomodulatory properties of diﬀ erent agents in highly controlled experimental 
conditions. Peripheral blood mononuclear cells (PBMC) have been used widely for 
screening of the ability of probiotics to induce cytokine production. A summary of 
the studies of probiotic-induced cytokine production in PBMC is presented in Table 
3. Probiotics in PBMC cultures are generally characterized by the induction of TNF-α; 
practically all strains are able to induce TNF-α (see Table 3). Most studied strains are 
Lactobacillus and Biﬁ dobacterium strains. 
In general, Biﬁ dobacterium strains have been very good inducers of anti-inﬂ ammatory 
IL-10 (Drouault-Holowacz et al., 2006; Foligne et al., 2007; Gackowska et al., 2006; Helwig 
et al., 2006; Lammers et al., 2003; Medina et al., 2007; Niers et al., 2005; O’Mahony et al., 
2006; Timmerman et al., 2007), although B. breve have also induced high concentrations 
of proinﬂ ammatory cytokines (Timmerman et al., 2007). Many Lactobacillus strains, 
L. casei (Niers et al., 2005; Shida et al., 2006b; Timmerman et al., 2007), L. plantarum 
(Helwig et al., 2006; Niers et al., 2005) and L. rhamnosus (Foligne et al., 2007; Hessle et 
al., 1999; Miettinen et al., 1998), have been good inducers of IL-10 as well. It has been 
found that L. rhamnosus strains are weaker IL-10 inducers than Biﬁ dobacterium strains 
(Helwig et al., 2006; Timmerman et al., 2007). L. delbrueckii (Castanheira et al., 2007) and 
L. acidophilus (Drouault-Holowacz et al., 2006; Foligne et al., 2007) strains have been 
weak inducers of anti-inﬂ ammatory IL-10. 
On the whole, Lactobacillus strains have been potent inducers of Th1-type cytokines. 
L. rhamnosus (Miettinen et al., 1998; Pochard et al., 2002), L. plantarum (Niers et al., 2005; 
Pochard et al., 2002) and L. acidophilus (Drouault-Holowacz et al., 2006; Foligne et al., 
2007; Gackowska et al., 2006) strains have induced IFN-γ. L. rhamnosus (Miettinen et 
al., 1998; Pochard et al., 2002), L. paracasei (Castellazzi et al., 2007; Hessle et al., 1999), 
L. plantarum (Foligne et al., 2007) and L. acidophilus (Drouault-Holowacz et al., 2006; 
Foligne et al., 2007; Gackowska et al., 2006) strains have been good inducers of IL-12. 
On the contrary, L. delbrueckii strains have decreased IL-12 and IFN-γ production 
(Castanheira et al., 2007) and induced IL-1β production (Lammers et al., 2003). In 
addition, L. plantarum strains have induced proinﬂ ammatory IL-6 (Niers et al., 2005) 
and IL-1β (Helwig et al., 2006; Lammers et al., 2003; Niers et al., 2005). The data on 
L. paracasei (Drouault-Holowacz et al., 2006; Timmerman et al., 2007), L. plantarum 
(Drouault-Holowacz et al., 2006; Timmerman et al., 2007), L. acidophilus (Helwig et al., 
2006; Lammers et al., 2003; Timmerman et al., 2007) and L. delbrueckii (Helwig et al., 
2006) strains is conﬂ icting as some studies have found them as weak inducers of any 
cytokines.
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Other strains are much less studied. E. coli has induced IL-10 and IL-1β production 
(Helwig et al., 2006). Lc. lactis strains have been investigated only in ﬁ ve studies (Foligne 
et al., 2007; Miettinen et al., 1998; Niers et al., 2005; Pochard et al., 2002; Timmerman 
et al., 2007). In these studies, Lc. lactis induced IL-10 production (Timmerman et al., 
2007) whereas in the other studies Lc. lactis strains were found potent inducers of IL-12 
(Foligne et al., 2007; Niers et al., 2005) and IFN-γ (Pochard et al., 2002). Streptococcus 
strains have only been examined in two studies; it has induced IL-10 and IL-1β 
(Lammers et al., 2003) or remained quite inert (Timmerman et al., 2007). Only two 
studies have addressed the eﬀ ect of probiotic combinations on cytokine production, 
and these studies have indicated similar or lower induction of cytokines compared to 
single strains (Castellazzi et al., 2007; Drouault-Holowacz et al., 2006).
Human monocytes, macrophages and dendritic cells have also been used for 
screening of cytokine production, although less extensively than PBMC. Virtually no data 
exists on human primary NK cells. In general terms, Gram-positive bacteria have been 
shown to be better inducers of IL-12 than Gram-negative bacteria in human monocytes 
(Hessle et al., 2000). L. rhamnosus GG has mainly induced proinﬂ ammatory cytokines 
in macrophages (Miettinen et al., 2000; Veckman et al., 2003). Cytokine responses in 
human dendritic cells have remained quite weak in Lactobacillus, Biﬁ dobacterium and 
Lactococcus strains (Niers et al., 2007; Veckman et al., 2004). 
Taken together, PBMC cultures have been used extensively to screen the induction 
of cytokines by probiotics. Probiotics in PBMC cultures are generally characterized 
by the induction of TNF-α, which may be due to the inﬂ ammatory response of 
PBMC to any stimulus. The discrimination between strains is therefore better 
realized by measuring other cytokines. Lactobacillus and Biﬁ dobacterium 
are the most studied strains and, in general, Lactobacillus strains are able to 
induce Th1 cytokines as well as IL-10 whereas Biﬁ dobacterium induce mainly 
anti-inﬂ ammatory IL-10. Other probiotic strains, such as Lactococcus and 
Streptococcus, have only been investigated in few studies and practically no data 
exists on the eﬀ ect of probiotic combinations (probiotic multispecies) compared 
with single strains (probiotic monostrain). 
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Probiotic strains Main fi ndings Reference
L. delbrueckii UFV H2b29 -IL-12, IFN-γ, TNF-α q
-IL-10 Pp
(Castanheira 
et al., 2007)
L. paracasei I 1688, 
L. salivarius I 1794 
and combination of them
-IL-12, IFN-γ Q with single strains and their combination (Castellazzi 
et al., 2007)
L. salivarius Ls33, 
L. rhamnosus Lr32,
L. casei B123, 
L. acidophilus NCFM, 
L. acidophilus IPL908, 
L. plantarum NCIMB8826,
L. plantarum Lp115, 
B. animalis ssp. lactis BL04, 
B. animalis ssp. lactis BI07, 
B. bifi dum BB02, 
Lc. lactis MG1363, 
E. coli TG1
-all strains TNF-α Q
-L. acidophilus IPL908, L. salivarius Ls33, L. rhamnosus Lr32, B. 
animalis ssp. lactis BL04 and B. bifi dum BB02 the most potent 
inducers of IL-10
-L. plantarum Lp115, L. plantarum NCIMB8826, B. animalis ssp. 
lactis BI07, L. acidophilus NCFM and Lc. lactis MG1363 the most 
potent inducers of IL-12
-IL-10/IL-12 ratio Q in L. acidophilus IPL908 and L. salivarius Ls33
(Foligne 
et al., 2007)
B. longum BB536, 
B. longum NCC 2705, 
B. longum W 11, 
B. longum ATCC 15707, 
B. longum BIR 324, 
B. longum BIF 53
-all strains TNF-α Q
-IL-2 and IFN-γ Q by B. longum W11 than by other strains
-IL-10 Q by B. longum NCIMB 8809 and BIF53 than by other 
strains
-IL-4 Pp
(Medina 
et al., 2007)
L. acidophilus,
E. coli Nissle
-intracellular IFN-γ/IL-4 ratio Q in lymphocytes in allergic patients 
but not in healthy
(Rasche 
et al., 2007)
L. acidophilus, 
L. brevis, 
L. bulgaricus,
L. casei, 
L. helveticus, 
L. paracasei, 
L. plantarum, 
L. rhamnosus, 
L. salivarius, 
B. bifi dum, 
B. breve, 
B. infantis, 
B. lactis,
B. longum, 
E. faecium,
Lc. lactis, 
S. thermophilus
-all strains TNF-α Q
-B. bifi dum, B. infantis, L. casei and Lc. lactis the most potent 
inducers of IL-10
-B. breve, L. brevis, L. rhamnosus and L. salivarius did not induce 
IL-10 
-B. breve, L. brevis and L. rhamnosus induced high concentrations 
of proinfl ammatory cytokines
(Timmerman 
et al., 2007)
L. acidophilus LA 201, 
L. plantarum LA 301,
L. salivarius LA 302, 
B. lactis LA 303, 
and combination of them
-all strains IL-12 and IL-10 Q
-L. salivarius and B. lactis IL-10/IL-12 ratio Q 
-cytokine production of the combination was an average of the 
single strains
(Drouault-
Holowacz 
et al., 2006)
L. salivarius UCC118, 
B. infantis 35624
-both TNF-α and IL-12 Q
-IL-10 Q by Bifi dobacterium than by Lactobacillus
(O’Mahony 
et al., 2006)
L. casei Shirota -TNF-α, IFN-γ, IL-12, IL-10 Q (Shida et al., 
2006b) 
Table 3. Eﬀ ect of probiotics on cytokine production in human peripheral blood mono-
nuclear cells. 
Continued
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Probiotic strains Main fi ndings Reference
L. acidophilus La-5R,
L. delbrueckii ssp. bulgaricus LbY-27, 
B. bifi dum Bb12 
and combination of them
-all strains and combination TNF-α and IL-10 Q
-L. acidophilus the strongest IFN-γ and IL-12 inducer
-cytokine production by bacterial combinations lower than in 
single strains
(Gackowska 
et al., 2006)
B. breve Y8, 
B. infantis Y 1, 
B. longum Y 10, 
E. coli Nissle 1917, 
L. acidophilus MB 443, 
L. rhamnosus GG, 
L. casei MB 451, 
L. delbrueckii ssp. bulgaricus MB 453,
L. plantarum MB 452
-IL-10, IL-1β, TNF-α Q by Bifi dobacteria and E. coli more 
than by Lactobacillus
-from lactobacilli IL-10, IL-1β, TNF-α Q by L. bulgaricus and 
L. plantarum more than by L. casei,L. acidophilus and 
L. rhamnosus 
(Helwig et al., 
2006)
Genomic DNAs of 
L. acidophilus LA14, 
L. delbrueckii ssp. bulgaricus LB31, 
L. casei LC10, 
L. plantarum LPT, 
B. infantis BI07, 
B. breve BSF, 
B. longum BL04, 
S. salivarius ssp. thermophilus TA061
- IL-10 Q by Bifi dobacterium and Streptococcus more than 
by Lactobacillus
- IL-6 q by Lactobacillus more than by Bifi dobacterium and 
Streptococcus 
-IL-1β Q B. breve, Streptococcus, L. plantarum and 
L. delbrueckii
(Lammers et 
al., 2003)
L. rhamnosus GG,
L. casei ATCC393, 
L. plantarum NCIMB8826, 
Lc. lactis MG1363
-IL-4 and IL-5 Pp
-all strains IFN-γ Q
-all strains IL-4 and IL-5 q when stimulated with allergen 
(Pochard et 
al., 2002)
L. johnsonii La 1, 
L. sakei LTH 681
-both TNF-α, IL-12, IFN-γ Q
-IL-10 Pp
(Haller et al., 
2000)
L. rhamnosus 50A, 
L. rhamnosus 7D, 
L. plantarum 52A, 
L. plantarum 67B, 
L. paracasei ssp. paracasei 02A, 
L. paracasei ssp. paracasei 34D
-IL-12 Q by L. paracasei more than by L. plantarum or 
L. rhamnosus
-IL-10 Q by L. rhamnosus more than by L. plantarum or 
L. paracasei
(Hessle et al., 
1999)
L. rhamnosus GG, 
L. rhamnosus E509, 
L. bulgaricus E585
-all strains TNF-α, IL-1β, IL-6, IL-18 and IL-10 Q
-IFN-γ and IL-12 Q by L. rhamnosus more than by other 
strains
-IL-4 Pp
(Miettinen et 
al., 1998)
L. rhamnosus GG,
L. rhamnosus E509, 
L. plantarum E98,
L. acidophilus E507, 
L. paracasei ssp. paracasei E506, 
L. paracasei ssp. paracasei E510, 
B. longum E505, 
B. animalis E508, 
Lc. lactis ssp. cremoris ARH74, 
Lc. lactis ssp. lactis E414
-all strains TNF-α and IL-6 Q
- L. rhamnosus E509, L. rhamnosus GG, B. animalis E508, 
L. acidophilus E507 were the best inducers of TNF-α
-L. rhamnosus E509, L. rhamnosus GG, B. animalis E508 
were the best inducers of IL-6
-live bacteria induced cytokine production better than 
glutaraldehyde-fi xed bacteria
(Miettinen et 
al., 1996)
Table 3. Continued
Q = increase; Pp = no induction; q = decrease
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2.2.4 Immunomodulatory properties in healthy adults
2.2.4.1 Assessment of the immunomodulatory eﬀ ects in probiotic interventions
Balanced and regulated immune and inﬂ ammatory responses are crucial for health, and 
diet is one of the major exogenous factors modulating immune responses. Assessing 
the eﬀ ect of probiotic intervention on the immune system requires a thorough 
methodological approach targeting a large spectrum of immunological parameters (for 
review, see Albers et al., 2005; Calder and Kew, 2002; Cummings et al., 2004). Currently, 
no single marker is available to predict the outcome of a probiotic intervention on 
immune function and resistance to infection or to other immune system-related 
diseases. Since nutrition inﬂ uences various components of inﬂ ammation, it may, 
together with several bioactive substances, such as probiotics, have a role in alleviating 
inﬂ ammatory conditions. Moreover, it may be used as a preventive therapy against 
diﬀ erent infections.
It is possible to assess the basal status of the immune system by measuring number 
of circulating leukocytes, lymphocyte subtypes, as well as the levels of immunoglobulins, 
cytokines and acute-phase proteins. However, it must be kept in mind that for example 
only 2% of lymphocytes at a given time are found in the circulation. In animal studies, 
it is also possible to asses the size of lymphoid organs and to collect and measure the 
function of immune cells from various organs. In humans, it is usually only possible to 
take blood, saliva, urine and faecal samples and in some cases biopsies of the gut. 
Especially in the case of probiotics, gut-associated markers of immune function 
are important. The integrity of the mucosal barrier can be assessed by the sugar 
permeability test. Secretory IgA in saliva can reﬂ ect the mucosal immune function. 
Measuring diﬀ erent inﬂ ammation markers, such as cytokines or calprotectin, 
from faeces may reﬂ ect possible inﬂ ammation in the gut. Mucosal histology and 
for example gene expression can be studied from biopsy specimens obtained from 
the gut. 
The activity and functional capacity of several immune system components can be 
studied in controlled conditions outside the body (ex vivo). Ex vivo markers of immune 
function provide information on the activity of speciﬁ c immune cells reﬂ ecting the 
capacity of either innate or adaptive immune responses. Examples of ex vivo measures 
include phagocytosis of neutrophils and monocytes, oxidative burst i.e. superoxide 
generation of neutrophils and monocytes, NK cell activity, lymphocyte proliferation 
and production of cytokines by peripheral blood mononuclear cells, monocytes or 
lymphocytes. The clinical relevance of changes in ex vivo markers is not clear, but they 
can provide important mechanistic information. 
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In vivo markers of immune function are best measured under controlled challenge 
conditions, such as vaccination (vaccine-speciﬁ c antibodies and vaccine-speciﬁ c 
antibody-forming cells) or intradermal application of an antigen (delayed-type 
hypersensitivity). With all of the diﬀ erent measures of immune function, it is worth 
remembering that normal ranges have only been established for a few of them, such as 
circulating cell numbers, immunoglobulins and CRP, but there are no normal ranges 
for instance for immune cell ex vivo functional responses. 
Finally, the clinical outcome i.e. the incidence, severity and duration of infection 
can be measured by questionnaires or diagnoses made by physician. The symptoms of 
infection, number of antibiotic prescriptions and absence from work or day care can 
also be measured as additional factors. The summary of markers of immunomodulation 
is presented in Table 4. 
In conclusion, to gain a comprehensive understanding of the immune 
function, it would be advisable to use a combination of measures of basal 
status of the immune system, gut-associated and ex vivo markers reﬂ ecting the 
functional capacity of cells of innate and adaptive immunity as well as clinical 
endpoints.
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Table 4. Summary of markers of immunomodulation (adapted from Albers et al., 2005; 
Calder and Kew, 2002; Cummings et al., 2004). 
Ex vivo
Clinical 
outcome/ 
questionnaires
Basal 
markers
Gut-
associated
Innate immune 
response
Adaptive 
immune 
response In vivo
Cell counts 
(differential 
leukocyte count, 
lymphocyte 
subpopulations)*
Secretory IgA in 
saliva/ faeces 
Oxidative 
burst activity 
of neutrophils/ 
monocytes
Lymphocyte 
proliferation 
Response to 
vaccination 
(vaccine-specifi c 
antibodies in 
serum, vaccine-
specifi c antibody-
forming cells)
Incidence, 
severity and 
duration of the 
infection
Circulating 
immunoglobulins
Mucosal 
histology 
(biopsy)
NK cell activity Lymphocyte 
antibody 
production 
following 
stimulation
Delayed-type 
hypersensitivity
Symptoms of the 
infection
Circulating 
cytokines**
Integrity of 
the mucosal 
barrier (sugar 
permeability 
test, bacterial 
permeability, 
serum 
endotoxins)
Cytokine 
production 
by PBMC, 
whole blood 
or monocytes 
following 
stimulation 
Lymphocyte 
cytokine 
production 
following 
stimulation 
Absence from 
work/school/
daycare
Circulating 
acute-phase 
proteins such as 
CRP***
Intestinal 
infl ammation 
(faecal 
calprotectin, 
cytokines)
Surface 
expression 
of activation 
markers involved 
in antigen 
presentation 
by antigen-
presenting cells
Lymphocyte 
activation 
(surface 
expression 
of activation 
markers)
Days with use of 
antibiotics
Complement 
activity
Chemotactic 
response of 
neutrophils/ 
monocytes
Cytotoxic T cell 
activity
Size of lymphoid 
organs
Eicosanoid 
production by 
neutrophils/ 
monocytes
Phagocytosis 
of neutrophils/ 
monocytes
* Facilitates interpretation of functional ex vivo markers
** Might be useful to measure under specifi c stress situations, such as exercise and fat-rich meals, known to cause an 
increase in proinfl ammatory cytokines
*** Not a marker of immune function but refl ects the presence of infl ammation or infection
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2.2.4.2 Immunomodulatory eﬀ ects of probiotics 
The immunomodulatory eﬀ ects of probiotics in healthy adults have not been 
extensively studied. The problem in the performed clinical studies is that in many 
cases they were not properly randomized and controlled. Only 15 studies in adults have 
been conducted in randomized, double-blind and placebo-controlled (RDBPC) clinical 
settings. Two RDBPC trials have been done in healthy children and one in the elderly. 
A summary of the RDBPC clinical studies on the eﬀ ect of probiotics on diﬀ erent aspects 
of immunomodulation (basal status of the immune system, gut-associated and ex vivo 
markers of immune function) is presented in Table 5 and a summary of the clinical 
studies performed in other clinical settings is presented in Table 6. A summary of the 
studies on the eﬀ ect of probiotics on in vivo markers of immune function is presented 
in Table 7. 
Basal status of the immune system 
In healthy adults, probiotics (diﬀ erent Lactobacillus and Biﬁ dobacterium strains, for 
details see Table 5 and 6) have usually had no eﬀ ect on the number of leukocytes or 
lymphocyte subpopulations (de Vrese et al., 2005b; de Vrese et al., 2006; Klein et al., 
2007; Lorea Baroja et al., 2007; Meyer et al., 2006; Olivares et al., 2006a; Olivares et 
al., 2006b; Parra et al., 2004a; Parra et al., 2004b; Roessler et al., 2008; Schiﬀ rin et al., 
1997; Spanhaak et al., 1998; Takeda and Okumura, 2007; Tiollier et al., 2007). However, a 
combination of L. gasseri PA16/8, B. longum SP07/3 and B. biﬁ dum MF20/5 (de Vrese et al., 
2005b; de Vrese et al., 2006) and L. casei DN114001 (Meyer et al., 2006) has been reported 
to increase the number of cytotoxic T cells and a combination of L. gasseri CECT 5714 
and L. coryniformis CECT 5711 has increased the number of NK cells (Olivares et al., 
2006a; Olivares et al., 2006b). A combination of L. gasseri CECT 5714 and L. coryniformis 
CECT 5711 has also increased serum IgA (Olivares et al., 2006a), whereas others reported 
no eﬀ ects on serum immunoglobulins by interventions with L. casei Shirota, L. casei 
DN114001 or a combination of B. animalis ssp. lactis Bb12 and L. paracasei ssp. paracasei 
CRL-431 (Christensen et al., 2006; Marcos et al., 2004; Pujol et al., 2000; Spanhaak et al., 
1998). L. casei Shirota has had no eﬀ ects on complement factors (Spanhaak et al., 1998), 
but L. rhamnosus GG has had diﬀ erential eﬀ ects on complement receptors in healthy 
and allergic adults; in healthy adults, the expression of complement receptors increased 
whereas it was down-regulated in allergic adults (Pelto et al., 1998). L. casei DN114001, 
L. casei Shirota, L. fermentum VRI003 or a combination of L. rhamnosus GR-1 and L. reuteri 
RC-14 have had no eﬀ ects on serum cytokine levels (Cox et al., 2008; Lorea Baroja et al., 
2007; Pujol et al., 2000; Takeda and Okumura, 2007), but a probiotic combination of 
L. gasseri and L. coryniformis has increased the IL-4 and IL-10 levels (Olivares et al., 2006a) 
and L. acidophilus has increased the IFN-γ level in saliva (Clancy et al., 2006). 
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The eﬀ ect of probiotics on acute-phase proteins has not been studied in healthy 
adults. Previously, the eﬀ ect of probiotics on CRP has only been examined in 
immunocompromised patients (Anderson et al., 2004; McNaught et al., 2005; McNaught 
et al., 2002; Reddy et al., 2007; Sugawara et al., 2006), allergic children (Viljanen et al., 
2005b) and patients suﬀ ering from rheumatoid arthritis (Hatakka et al., 2003) and 
ulcerative colitis (Furrie et al., 2005). In immunocompromised patients, a combination 
of L. casei Shirota, B. breve Yakult and prebiotic galactooligosaccharides (Sugawara et al., 
2006) and in patients with ulcerative colitis B. longum (Furrie et al., 2005) have reduced 
serum CRP levels and also resulted in improvement in the overall clinical appearance of 
chronic inﬂ ammation (Furrie et al., 2005). In contrast to the above-mentioned studies, 
L. rhamnosus GG has increased serum CRP levels compared with placebo in infants with 
IgE-associated atopic eczema dermatitis syndrome (Viljanen et al., 2005b). However, 
L. rhamnosus GG had no eﬀ ect on serum CRP levels in patients with rheumatoid arthritis 
(Hatakka et al., 2003). It is of interest that a combination of four probiotic bacteria 
(L. rhamnosus GG, L. rhamnosus Lc705, B. breve Bb99 and P. freudenreichii ssp. shermanii JS) 
had no eﬀ ect on sensitive CRP levels in blood (Viljanen et al., 2005b) in the same clinical 
setting with the allergic children. Furthermore, neither L. plantarum 299V (McNaught 
et al., 2005; McNaught et al., 2002) nor a combination of L. acidophilus La5, B. animalis 
ssp. lactis Bb12, S. thermophilus and L. bulgaricus (Anderson et al., 2004; Reddy et al., 2007) 
changed serum CRP concentrations in immunocompromised patients undergoing 
surgical procedures. It would seem that the eﬀ ect of probiotics on CRP as an example 
of the acute-phase proteins is controversial in diﬀ erent diseases and no data on the 
eﬀ ects in healthy adult population is available.
Gut-associated markers of immune function
Not many studies assessing the eﬀ ect on gut-associated markers, such as salivary IgA 
or gut permeability, have been performed in healthy adults, and the results are quite 
conﬂ icting. There are indications that L. casei DN114001 might prevent the decrease 
of salivary IgA in heavily training men (Tiollier et al., 2007), while L. fermentum VRI003 
had no eﬀ ect on salivary IgA in another study in elite male distance runners (Cox 
et al., 2008). L. rhamnosus GG has been reported to decrease the non-steroidal anti-
inﬂ ammatory drug (NSAID)-induced gastric permeability (Gotteland et al., 2001). 
Only two studies have examined the eﬀ ects of probiotic intervention on gut mucosa 
from biopsies. In duodenal mucosa biopsies, L. rhamnosus GG aﬀ ected mainly genes 
involved in immune response and inﬂ ammation (TGF-β, TNF family members, 
cytokines, nitric oxide synthase 1, defensin alpha1), apoptosis, cell growth and cell 
diﬀ erentiation (cyclins, caspases, oncogenes), cell signalling (ICAMs and integrins), 
cell adhesion (cadherins), signal transcription and transduction (Di Caro et al., 2005). 
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L. reuteri has induced the numbers of duodenal B lymphocytes and ileal CD4+ T 
lymphocytes and decreased the number of mucosal histiocytes in gastric mucosa 
(Valeur et al., 2004).
Ex vivo markers of immune function 
Quite many studies have investigated the eﬀ ects of probiotics on the ex vivo functional 
responses of speciﬁ c immune cells, especially the activity of the cells of innate immunity, 
in healthy adults. It seems that probiotics (diﬀ erent Lactobacillus and Biﬁ dobacterium 
strains, for details see Table 5 and 6) are able to increase the phagocytic activity of 
macrophages and granulocytes (Arunachalam et al., 2000; Chiang et al., 2000; Donnet-
Hughes et al., 1999; Klein et al., 2007; Olivares et al., 2006a; Olivares et al., 2006b; 
Roessler et al., 2008; Schiﬀ rin et al., 1997; Sheih et al., 2001; Takeda and Okumura, 2007), 
although there are also studies in which no eﬀ ects have been found (Christensen et 
al., 2006; de Vrese et al., 2005b; de Vrese et al., 2006). L. casei DN114001 intervention 
has been reported to increase the oxidative burst activity (Parra et al., 2004a; Parra et 
al., 2004b) and NK cell activity (Parra et al., 2004b). A combination of L. gasseri PA16/8, 
B. longum SP07/3 and B. biﬁ dum MF20/5 has had no eﬀ ects on T cell activation (de Vrese 
et al., 2005b; de Vrese et al., 2006). 
The eﬀ ect of probiotics on the ex vivo cytokine production by immune cells has 
been investigated only in a few studies. A combination of B. animalis ssp. lactis Bb12 and 
L. paracasei ssp. paracasei CRL-431 has had no eﬀ ects on ex vivo cytokine production by 
whole blood cells in young healthy adults (Christensen et al., 2006), while B. lactis HN019 
has increased ex vivo IFN-α production by PBMC in healthy elderly (Arunachalam 
et al., 2000). L. casei DN114001 has had no eﬀ ect on ex vivo cytokine production by 
PBMC (Marcos et al., 2004), but L. rhamnosus GG has decreased the production of 
proinﬂ ammatory cytokines and increased anti-inﬂ ammatory cytokines production by 
PBMC (Schultz et al., 2003). In another trial, L. rhamnosus GG decreased the ex vivo 
cytokine production by PBMC both in healthy adults and patients with Crohn’s disease 
(Braat et al., 2004).
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Table 5. Eﬀ ect of probiotics on basal status, gut-associated and ex vivo markers of 
immune function in randomized, double-blind, placebo-controlled clinical settings in 
healthy adults, elderly and children. Statistically signiﬁ cant diﬀ erence is indicated with 
bold font.
Subjects
Design and 
duration
Probiotic 
strains Main fi ndings Reference
Healthy 
adults, 
n=122
R, DB, PC
14 d
Combination of 
L. gasseri PA16/8, 
B. longum SP07/3, 
B. bifi dum MF20/5 
and vitamins 
+minerals or placebo
-cytotoxic T cells Q
-lymphocytes, T lymphocytes, 
B lymphocytes, T helper cells, NK cells Pp
-phagocytic activity of macrophages and 
granulocytes Pp
-T cell activation Pp
(de Vrese et al., 
2005b)
Healthy 
adults, 
n=122
R, DB, PC
14 d
Combination of 
L. gasseri PA16/8, 
B. longum SP07/3, 
B. bifi dum MF20/5 
and vitamins 
+minerals or placebo
-cytotoxic T cells Q
-lymphocytes, T lymphocytes, 
B lymphocytes, T helper cells, NK cells Pp
-phagocytic activity of macrophages and 
granulocytes Pp
-T cell activation Pp
(de Vrese et al., 
2006)
Healthy 
adults,
n=30
R, DB, PC
1 mo
Combination of L.
gasseri CECT 5714 
and L. coryniformis 
CECT 5711 or 
placebo
-NK cells Q
-lymphocytes, T cells, cytotoxic T cells, 
T helper cells, B cells, memory T cells, 
suppressor T cells Pp
-serum IgA Q
-serum IgG, IgE Pp
-serum IL-10, IL-4 Q
-serum TNF-α, IL-12 Pp
- phagocytic activity of macrophages 
and granulocytes Q (both groups)
(Olivares et al., 
2006a)
Healthy 
adults,
n=26
R, DB, PC, 
C-O
1 mo
Combination of L. 
acidophilus 74-2 
and B. animalis ssp. 
lactis DGCC 420 or 
placebo
-lymphocytes, monocytes, granulocytes, 
T cells, B cells, T helper cells, cytotoxic 
T cells, NK cells, activated T cells Pp
-phagocytic activity of granulocytes and 
monocytes Q
-oxidative burst activity of monocytes and 
granulocytes Pp
(Klein et al., 
2007)
Healthy 
adults, n=15
Adults 
with atopic 
dermatitis,
n=15
R, DB, PC
2 mo
Combination of L. 
paracasei Lpc-37, 
L.acidophilus 74-2 
and B. animalis ssp. 
lactis DGCC 420
-natural killer cell marker CD57+ Q 
(healthy)
- CD4+ T lymphocytes expressing CD54+ 
(ICAM-1) q (atopic)
-major leukocyte subsets, lymphocytes, 
T cells, B cells, cytotoxic T cells, NK cells, 
activated T cells, suppressor/cytotoxic
T cells bearing CD57+ and CD54 
(ICAM-1) Pp
- phagocytic activity of monocytes and 
granulocytes Q (healthy)
(Roessler et al., 
2008)
Healthy 
middle aged 
adults, 
n=45
R, DB, PC
2 mo
L. casei DN114001 
or placebo
-white blood cell count, T cells, activated 
T cells, B cells, T helper cells, cytotoxic 
T cells, NK cells Pp
-oxidative burst capacity of monocytesQ
-NK cells tumoricidal activity Q
(Parra et al., 
2004b)
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Continued
Subjects
Design and 
duration
Probiotic 
strains Main fi ndings Reference
Healthy middle- 
aged adults, 
n=45
R, DB, PC
2 mo
L. casei DN114001 
or placebo
-white blood cell count, T cells, 
activated T cells, B cells, T helper 
cells, cytotoxic T cells, NK cells Pp
-oxidative burst capacity of 
monocytes and granulocytes Q
(Parra et al., 
2004a)
Healthy men in 
French Commando 
training,
n=47
R, DB, PC
1 mo
L. casei DN114001 
or placebo
-leukocytes, leukocyte subsets, 
T cells, T helper cells, cytotoxic 
T cells, NK cells Pp
-salivary IgA q in placebo but 
not in probiotic group
(Tiollier et al., 
2007)
Healthy elite male 
distance runners,
n=20
R, DB, PC,
C-O
1 mo
L. fermentum VRI003 
or placebo
-serum IL-4, IL-12 Pp
-tendency for Q IFN-γ in whole 
blood culture
-salivary IgA Pp
(Cox et al., 2008)
Adults (heavy 
smokers), 
n=36
R, DB, PC
1,5 mo
L. plantarum 299v or 
placebo
-production of intracellular reactive 
oxygen species by monocytes Pp
-plasma F2-isoprostane q
-plasma IL-6 q
(Naruszewicz et 
al., 2002)
Young healthy 
adults,
n=71
R, DB, PC 
3 wk 
(dose–
response)
A mixture of 
B. animalis ssp. 
lactis Bb-12 and 
L. paracasei ssp. 
paracasei CRL-431
-faecal IgA concentrations Pp
-serum IgA, IgM, IgG Pp
-phagocytic activity in
blood leukocytes Pp
-IFN-γ and IL-10 production from 
in vitro stimulated whole blood Pp
(Christensen et 
al., 2006) 
Healthy milk- 
tolerant adults n=9
Milk- hypersensitive 
adults n=8
R, DB, PC, 
C-O
2 wk 
(1 wk wash-
out)
L rhamnosus GG or 
placebo
-in healthy expression of 
complement receptors on 
neutrophils and monocytes Q
-in milk-hypersensitive 
prevented Q of complement 
receptor expression on 
neutrophils and monocytes
(Pelto et al., 
1998)
Healthy children, 
n=154
R, DB, PC
1 mo
L. rhamnosus GG or 
placebo
-intestinal integrity (sugar 
permeability test) Pp
(Galpin et al., 
2005)
Healthy elderly,
n=25
R, DB, PC
1,5 mo
B. lactis HN019 or 
placebo
-phagocytic activity Q
-ex vivo production of IFN-α Q 
by PBMC
(Arunachalam et 
al., 2000)
R = randomized; DB = double-blind; PC = placebo-controlled; C-O = cross-over 
Q = increase; Pp = no induction; q = decrease
Table 5. Continued
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Subjects
Design and 
duration
Probiotic 
strains Main fi ndings Reference
Healthy males, 
n=6
R, PC
1 mo
L. rhamnosus GG or 
placebo
-in biopsies from duodenal mucosa 
LGG affected mainly genes 
involved in immune response 
and infl ammation (TGF-β, TNF 
family members, cytokines, nitric 
oxide synthase 1, defensin alpha1), 
apoptosis, cell growth and cell 
differentiation (cyclins, caspases, 
oncogenes), cell signaling (ICAMs 
and integrins), cell adhesion 
(cadherins) signal transcription and 
transduction
(Di Caro et al., 
2005)
Healthy adults, 
n=10
O
1 mo
L. rhamnosus GG -TNF-α, IL-6, IFN-γ secretion by 
peripheral blood cells q
-IL-4, IL-10 secretion by 
peripheral blood cells Q
-helper T cell activation Q
(Schultz et al., 
2003)
Healthy adults, 
n=6
Patients with 
Crohn’s disease, 
n=6
O
2 wk
L. rhamnosus GG -In healthy adults ex vivo 
production of IL-2, IL-4 and IL-10 
by T cells q
-In Crohn’s disease patients 
production of IL-2, IFN-γ, IL-10 
by T cells q
-TGF-β production Pp
(Braat et al., 
2004)
Healthy adults, 
n=16
R
5 d
NSAID 
or NSAID with 
L. rhamnosus GG
-strengthening of gastric 
mucosal barrier (sugar 
permeability test) Q
-strengthening of intestinal mucosal 
barrier (sugar permeability test) Pp
Gotteland et al., 
2001)
Healthy adults, 
n=20
Patients with 
infl ammatory 
bowel disease 
(IBD), n=20
O
1 mo
Combination of 
L. rhamnosus GR-1 
and 
L. reuteri RC-14
-Treg cells (CD4+ CD25high) Q 
(IBD)
-TNF-α and IL-12-producing 
monocytes and dendritic 
cells q (IBD)
-serum IL-12 q (IBD)
-T cell surface activation markers
-ex vivo proliferative responses of 
PBMC Pp
(Lorea Baroja et 
al., 2007)
Healthy,
n=10
Ileostomy 
patients, n=9
O
1 mo
(biopsy before 
and after 
supplementation)
L. reuteri -gastric mucosal histiocyte 
numbers q
-duodenal B lymphocytes Q
-ileal CD4+ T lymphocytes Q
(Valeur et al., 
2004)
Table 6. Eﬀ ects of probiotics on basal status, gut-associated and ex vivo markers of 
immune function in other clinical settings in healthy adults and children. Statistically 
signiﬁ cant diﬀ erence is indicated with bold font.
Continued
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Subjects
Design and 
duration
Probiotic 
strains Main fi ndings Reference
Healthy students,
n=155
R, C
1,5 mo
(under academic 
examination 
stress)
L. casei DN114001 milk 
or milk
-NK cells Q
-T cells, T helper cells, cytotoxic 
T cells, B cells Pp
-leukocytes, granulocytes, 
monocytes, lymphocytes Pp
-serum IgA, IgM, IgG Pp
-phagocytosis and oxidative burst 
of leukocytes Pp
-IL-2, IFN-γ, TNF-α, IL-4, IL-5, 
IL-10 cytokine production by 
PBMC Pp
(Marcos et al., 
2004)
Young healthy 
women,
n=33
R, C
2 wk 100g + 
2 wk 200g
L. casei DN114001 
yoghurt or conventional 
yoghurt
-cytotoxic T cells Q
-leukocytes, granulocytes, 
monocytes, lymphocytes, 
T lymphocytes, regulatory T cells, 
T helper cells, NK cells Pp
(Meyer et al., 
2006)
Healthy athletes 
having low NK 
cell numbers 
selected (from 99 
athletes),
n=25
O, C
1 mo, 
ergometer stress 
test in the end of 
study periods
L. casei DN114001 or 
milk
-numbers of T cells, T helper cells, 
B cells, NK cells Pp
-serum IgA, IgM, IgG Pp
-serum IL-1β, sIL-2r, IL-6, IL-2, 
IFN-γ Pp
-NK cell cytotoxic activity Pp
(Pujol et al., 
2000)
Healthy males,
n=20
R, PC
1 mo
L. casei Shirota 
or placebo
-T cells, T helper cells, cytotoxic 
T cells, NK cells and B cells Pp
-serum IgM, IgG, IgA, IgD and 
IgE Pp
-complement factors C3, C4 and 
factor B Pp
-NK cell activity Pp
-phagocytosis and oxidative burst 
of neutrophils Pp
-IL-1β, IL-2, IFN-γ production by 
PBMC Pp
(Spanhaak et 
al., 1998)
Healthy adults, 
n=41
Healthy children, 
n=36
SB, C-O
1 mo
L. casei 
or combination of 
L. casei, 
L. acidophilus LA8F, 
B. animalis ssp. lactis 
BLi8F, B. breve BBr8F 
and B. breve BBl8F 
-secretory IgA in saliva Q 
(children) (ns between groups)
-NK cell activity Q (adults) (ns 
between groups)
(Zanini et al., 
2007)
Healthy adults,
n=50
R
3 wk
B. lactis HN019 
in milk or 
B. lactis HN019 
in lactose-hydrolyzed 
milk
-polymorphonuclear cells 
phagocytosis Q (lactose-
hydrolyzed milk)
 -NK cell tumour killing activity Q 
(lactose-hydrolyzed milk)
(Chiang et al., 
2000)
Healthy elderly,
n=27
R
3 wk
L. rhamnosus HN001 or 
B. lactis HN019
-NK cell activity Q both 
probiotics
(Gill et al., 
2001a)
Table 6. Continued
Continued
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Subjects
Design and 
duration
Probiotic 
strains Main fi ndings Reference
Healthy elderly,
n=30
R
3 wk
B. lactis HN019 5x1010 
or 
B. lactis HN019 5x109
-NK cell activity Q (both doses)
-T cells, T helper cells, activated 
T lymphocytes, NK cells Q (both 
doses)
-cytotoxic T cells, B cells Pp
-phagocytic activity of 
leukocytes Q (both doses)
(Gill et al., 
2001b)
Healthy adults,
n=28
R
3 wk
L. acidophilus La1 or 
B. bifi dum Bb12
-lymphocytes, T cells, activated 
T cells, B cells, T helper cells, 
cytotoxic T cells, NK cells Pp
-leukocyte phagocytic activity Q 
(both probiotics)
(Schiffrin et al., 
1997)
Healthy adults,
n=42
R, O
3 wk
S. thermophilus, 
L. johnsonii La1 
106 cfu/ml or 
L. johnsonii La1 
107 cfu/ml
-phagocytic activity of peripheral 
blood cells and of monocytes 
and granulocytes Q (L. johnsonii 
La1 107 cfu/ml)
-leukocyte respiratory burst 
activity Q (L. johnsonii La1 107 
cfu/ml)
(Donnet-
Hughes et al., 
1999)
Healthy athletes, 
n=18
Fatigued 
athletes, 
n=9
O
1 mo
L. acidophilus 
LAFTI®L10
-salivary IFN-γ Q (healthy)
-secretion of IFN-γ by helper T 
cells from whole blood culture Q 
(fatigued)
-secretion of IL-4, IL-12 by helper T 
cells from whole blood culture Pp
-salivary IgA Pp
(Clancy et al., 
2006)
Healthy adults,
n=30
R, PC
2 wk 
supplementation 
after 2 wk 
deprivation diet 
of fermented 
food
Combination of 
L. gasseri CECT 5714 
and L. coryniformis 
CECT 5711 or placebo
-NK cells Q
-lymphocytes, T cells, cytotoxic 
T lymphocytes, T helper cells, B 
cells, memory T cells, activated T 
cells Pp
- phagocytic activity of 
monocytes and granulocytes Q 
(both groups)
(Olivares et al., 
2006b)
Table 6. Continued
R = randomized; PC = placebo-controlled; SB = single-blind; C = controlled; O = open C-O = cross-over
Q = increase; Pp = no change; q = decrease
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In vivo markers of immune function
The eﬀ ect of probiotics on the in vivo markers of immune function (response to 
vaccines, delayed type hypersensitivity and response to attenuated pathogens) in 
healthy population has not been extensively studied (Table 7). There are indications that 
probiotics may increase the vaccine-speciﬁ c antibodies after vaccinations. L. rhamnosus 
GG has been reported to increase vaccine-speciﬁ c antibodies after oral polio vaccine 
in adults (de Vrese et al., 2005a) and after oral rotavirus vaccine in children (Isolauri et 
al., 1995), whereas L. fermentum ECT5716 has increased vaccine-speciﬁ c antibodies after 
intramuscular anti-inﬂ uenza vaccine in adults (Olivares et al., 2007). L. rhamnosus GG 
or Lc. lactis intervention had no eﬀ ects on Salmonella typhi speciﬁ c antibodies after oral 
S. typhi vaccination (He et al., 2000), but a combination of B. animalis ssp. lactis Bb12 
and L. acidophilus LA-1 increased S. typhi speciﬁ c IgA after administration of attenuated 
S. typhi bacteria (Link-Amster et al., 1994).
Taken together, not many randomized, double-blind, placebo-controlled 
studies have addressed the immunomodulatory eﬀ ects of probiotics in healthy 
adults. There are indications that probiotics could aﬀ ect the functional responses 
of immune cells, especially the activity of the cells of innate immunity. There are 
also indications that probiotics could be used as adjuvants for vaccines. The 
eﬀ ect of probiotics on CRP in healthy adults has not been studied previously. 
It is clear that immunomodulatory eﬀ ects are strain-speciﬁ c and therefore each 
probiotic monostrain as well as probiotic multispecies should be evaluated 
individually. 
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Subjects
Design and 
duration
Probiotic 
strains Main fi ndings Reference
Healthy males, 
n=43
R, DB, PC
5 wk
(oral polio 
vaccine)
L. rhamnosus GG or 
placebo
-poliovirus neutralizing antibody 
titer Q
-serum poliovirus-specifi c IgA Q 
(de Vrese et 
al., 2005a)
Healthy adults, 
n=30
R, DB, PC
1 wk
(oral Salmonella 
typhi vaccine)
L. rhamnosus GG, 
Lc. lactis 
or placebo
-IgA, IgG, IgM-secreting cells Pp
-complement receptor CR3 
expression Q (L. lactis)
-IgG receptors on neutrophils and 
monocytes Pp
(He et al., 
2000)
Healthy infants, 
n=57
R, DB, PC
5 d
(oral rotavirus 
vaccine)
L. rhamnosus GG or 
placebo
-number of rotavirus-specifi c 
IgM-secreting cells Q
-trend towards Q IgA
(Isolauri et al., 
1995)
Healthy adults, 
n=50
R, DB, PC
1 mo 
+ 5 mo follow-up
(intramuscular 
anti-infl uenza 
vaccine)
L. fermentum ECT5716 
or placebo
-T cells, cytotoxic T cells, T helper 
cells, B cells, memory T cells Pp
-NK cells Q
-serum TNF-α Q
-serum IFN-γ, IL-12, IL-10 Pp
-serum anti-infl uenza–specifi c 
IgA Q
-serum anti-infl uenza–specifi c IgG, 
IgM Pp
-serum IgA, IgG Pp
-serum IgM Q
(Olivares et al., 
2007)
Healthy adults,
n=30
R, C
3 wk
(attenuated 
Salmonella typhi 
administration)
Combination of 
B. lactis ssp. animalis 
Bb12 and L. acidophilus 
LA-1 or control without 
fermented foods
-serum S. typhi specifi c IgA Q
-serum IgA Q
(Link-Amster 
et al., 1994)
Healthy males,
n=20
R, PC
1 mo
L. casei Shirota 
or placebo
-delayed type hypersensitivity Pp (Spanhaak et 
al., 1998)
Table 7. Eﬀ ect of probiotics on in vivo markers of immune function in healthy adults 
and children. Statistically signiﬁ cant diﬀ erence is indicated with bold font.
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2.2.4.3 Eﬀ ect of probiotics on clinical outcome
Respiratory infections
There is increasing evidence that probiotics may provide protection against respiratory 
tract infections and common colds. The eﬀ ect of probiotics in prevention of respiratory 
infections has been investigated in seven studies in healthy adults, two in the elderly 
and in four studies in children. In adults, L. fermentum CETC5716 have reduced the 
incidence of respiratory infection (Olivares et al., 2007), and L. fermentum VRI003 the 
number of days with respiratory symptoms (Cox et al., 2008), while in other studies 
there was no reduction in the number of respiratory infections by a combination of 
L. gasseri PA16/8, B. longum SP07/3 and B. biﬁ dum MF20/5 or by L. casei DN114001 (de Vrese 
et al., 2005b; de Vrese et al., 2006; Tiollier et al., 2007; Winkler et al., 2005). However, a 
combination of L. gasseri PA16/8, B. longum SP07/3 and B. biﬁ dum MF20/5 has reduced 
the duration (de Vrese et al., 2005b; de Vrese et al., 2006) or symptoms (de Vrese et 
al., 2005b; Winkler et al., 2005) of respiratory infection and L. reuteri has reduced the 
absence from work in adults (Tubelius et al., 2005). In the elderly, L. casei DN114001 
intervention decreased the incidence of infection but had no eﬀ ect on the duration of 
infection (Turchet et al., 2003) while a combination of L. rhamnosus GG, L. rhamnosus 
Lc705, B. breve Bb99 and P. freudenreichii ssp. shermanii JS was ineﬀ ective in prevention 
of respiratory infections in the elderly (Hatakka, 2007). In children, L. rhamnosus GG, 
L. casei DN114001 and a combination of L. rhamnosus GG, L. rhamnosus Lc705, B. 
breve Bb99 and P. freudenreichii ssp. shermanii JS reduced the incidence of respiratory 
infections (Cobo Sanz et al., 2006; Hatakka, 2007; Hatakka et al., 2001). Treatment with 
L. rhamnosus GG or a combination of L. reuteri SD112 and B. lactis Bb12 has resulted in 
fewer days of absence from day care due to illness (Hatakka et al., 2001; Weizman et al., 
2005). A summary of the studies on probiotics in preventing respiratory infections is 
presented in Table 8. 
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Subjects
Design and 
duration
Probiotic 
strains Main fi ndings Reference
Adults
Healthy adults, 
n=262
R, DB, PC
2,5 mo
L. reuteri 
or placebo
-sick-leave q
-duration of sick-leave Pp
(Tubelius et 
al., 2005)
Healthy adults, 
n=477
R, DB, PC
3-5,5 mo
Combination of 
L. gasseri PA16/8, 
B. longum SP07/3, 
B. bifi dum MF20/5 and 
vitamins+minerals 
or placebo
-incidence and duration of respiratory 
infection Pp
-days with fever q
(Winkler et 
al., 2005)
Healthy adults, 
n=479
R, DB, PC
3 mo
Combination of 
L. gasseri PA16/8, 
B. longum SP07/3, 
B. bifi dum MF20/5 and 
vitamins+minerals 
or placebo
-incidence of respiratory infection Pp
-duration of respiratory infection q
-symptom score Pp
-days with fewer q 
-bronchial symptoms q
(de Vrese et 
al., 2005b)
Healthy adults, 
n=479
R, DB, PC
3-5 mo
Combination of 
L. gasseri PA16/8, 
B. longum SP07/3, 
B. bifi dum MF20/5 and 
vitamins+minerals 
or placebo
-incidence of respiratory infection Pp
-duration of respiratory infection q
-symptom score Pp
-bronchial symptoms q
(de Vrese et 
al., 2006)
Healthy adults, 
n=50
R, DB, PC
1 mo
+ 5 mo follow-up
(intramuscular anti-
infl uenza vaccine)
L. fermentum 
CECT5716 or placebo
- number of respiratory 
infections q
(Olivares et 
al., 2007)
Healthy elite 
male distance 
runners,
n=20
R, DB, PC,
C-O
1 mo
L. fermentum VRI 003 
or placebo
-incidence of respiratory infections Pp
-number of days with respiratory 
symptoms q
-severity of symptoms Pp
(Cox et al., 
2008)
Healthy men 
in French 
Commando 
training,
n=47
R, DB, PC
1 mo
L. casei DN114001 
or placebo
-incidence of respiratory infection Pp
-proportion of rhinopharyngitis Q
-symptoms of infection Pp
(Tiollier et al., 
2007)
Elderly
Healthy elderly, 
n=260
R, C
3 wk
L. casei DN114001 
and control group
-incidence of respiratory infection Pp
-duration of respiratory infection q
(Turchet et 
al., 2003)
Institutionalized 
elderly,
n=265
R, DB, PC
5 mo
Combination of 
L. rhamnosus GG, 
L. rhamnosus Lc705, 
B. breve Bb99, 
P. freudenreichii ssp. 
shermanii JS 
or placebo
-incidence of respiratory infection Pp
-duration of respiratory infection Q
(Hatakka, 
2007)
Table 8. Eﬀ ects of probiotics on prevention of respiratory infections in clinical 
settings in healthy adults, elderly and children. Statistically signiﬁ cant diﬀ erence 
is indicated with bold font.
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Continued
Subjects
Design and 
duration
Probiotic 
strains Main fi ndings Reference
Children
Healthy day 
care children,
n=571
R, DB, PC
7 mo
L. rhamnosus GG 
or placebo
-respiratory infections q
-absence from day care due to 
illness q
-antibiotic treatments q
(Hatakka et 
al., 2001)
Healthy, otitis- 
prone children, 
n=309
R, DB, PC
6 mo
Combination of 
L. rhamnosus GG, 
L. rhamnosus Lc705, 
B. breve Bb99, 
P. freudenreichii ssp. 
shermanii JS 
or placebo
-occurrence or
duration of acute otitis media Pp
-occurrence of recurrent 
respiratory infections q
(Hatakka, 
2007)
Healthy infants, 
n=201
R, DB, PC
3 mo
L. reuteri SD 112 
or B. lactis Bb12 
or placebo
-respiratory infections Pp
-absence from day care due to 
illness q (L. reuteri)
-antibiotic treatments q (L. reuteri)
(Weizman et 
al., 2005)
Healthy school 
children, 
n=251
R, DB, PC
5 mo
L. casei DN114001 
or placebo
-incidence and duration of respiratory 
infection or GI infection Pp
-incidence of lower respiratory 
infection and fatigue q
(Cobo Sanz 
et al., 2006)
Table 8. Continued
R = randomized; DB = double-blind; PC = placebo-controlled; C-O = cross-over; C = controlled
Q = increase; Pp = no change; Q = decrease
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Gastrointestinal symptoms and infections
Probiotics have been most extensively studied in the treatment of diarrhoeal diseases, 
where their eﬃ  cacy can be considered well established. Probiotics, especially 
Lactobacillus and Biﬁ dobacterium strains, have prevented and reduced the duration of 
infectious, hospital-acquired diarrhoea (for review, see Guandalini, 2006; Sazawal et 
al., 2006; Szajewska et al., 2001), traveller’s diarrhoea (for review, see McFarland, 2007; 
Sazawal et al., 2006) and antibiotic-associated diarrhoea (for review, see Sazawal et 
al., 2006). The eﬀ ect of probiotics on community-acquired diarrhoea has not been 
extensively studied. Only one study in healthy adults, two in the elderly and six studies 
in children have been conducted. Of these, only two interventions, one with L. casei 
DN114001 and the other with a combination of L. reuteri SD112 and B. lactis Bb12 
were eﬀ ective in decreasing the number of diarrhoea in children (Pedone et al., 2000; 
Weizman et al., 2005). There is more evidence that probiotics could decrease the duration 
of community-acquired diarrhoea. In children, L. casei DN114001, B. lactis Bb12 and a 
combination of L. reuteri SD112 and B. lactis Bb12 (Chouraqui et al., 2004; Pedone et al., 
1999; Weizman et al., 2005) and L. casei DN114001 in the elderly (Turchet et al., 2003) 
have decreased the duration of diarrhoea. A summary of the studies in the prevention 
of community-acquired diarrhoea by probiotics is presented in Table 9. 
To summarize, mainly Lactobacillus and Biﬁ dobacterium strains or 
combinations thereof have been used for studying the preventive eﬀ ects of 
probiotics on respiratory infections. There are indications that probiotics could 
reduce especially the duration of respiratory infections in healthy population. 
Virtually no data on the prevention of community-acquired diarrhoea or 
gastrointestinal symptoms in healthy adults is available, but probiotics have 
strain-speciﬁ cally reduced the duration or incidence of community-acquired 
diarrhoea in healthy children. 
Subjects Design and 
duration
Probiotic strains Main fi ndings Reference
Adults
Men in military 
camps,
n=502
R, PC
2 mo
L. casei DN114001 
or placebo
-incidence and duration of 
diarrhoea Pp
(Pereg et al., 
2005)
Elderly
Healthy elderly, 
n=260
R, C
3 wk
L. casei DN114001 
and control group
-incidence of GI infection Pp
-duration of GI infection q
(Turchet et 
al., 2003)
Institutionalized 
elderly,
n=265
R, DB, PC
5 mo
Combination of 
L. rhamnosus GG, 
L. rhamnosus Lc705, 
B. breve Bb99, 
P. freudenreichii ssp. 
shermanii JS 
or placebo
-incidence of GI infection Pp
-duration of GI infection Pp
(Hatakka, 
2007)
Children
Healthy infants 
and children, 
n=928
R, DB, PC
4 mo
L. casei DN114001 
or placebo
-incidence of diarrhoea q (Pedone et 
al., 2000)
Healthy infants 
and children,
n=287
R, PC
19 mo
L. casei DN-114001 
or placebo
-incidence of diarrhoea Pp
-duration of diarrhoea q
(Pedone et 
al., 1999)
Healthy 
children, 
n=154
R, DB, PC
1 mo
L. rhamnosus GG 
or placebo
-incidence of diarrhoea Pp (Galpin et al., 
2005)
Healthy infants, 
n=201
R, DB, PC
3 mo
L. reuteri SD 112 
or B. lactis Bb12 
or placebo
-episodes and duration of diarrhea 
in probiotic groups q
(Weizman et 
al., 2005)
Healthy infants, 
n=90
R, DB, PC
4,5 mo
B. lactis Bb12 
or placebo
-incidence of diarrhoea Pp 
-duration of diarrhoea q
(Chouraqui et 
al., 2004)
Healthy infants, 
n=971
R, DB, PC
5 mo
Combination of 
B. breve and 
S. thermophilus 
or placebo
-incidence and duration of 
diarrhoea Pp
(Thibault et 
al., 2004)
Table 9. Eﬀ ect of probiotics on prevention of community-acquired diarrhea and gas-
trointestinal infections in clinical settings in healthy adults, the elderly and children. 
Statistically signiﬁ cant diﬀ erence is indicated with bold font.
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2.2.5 Safety of probiotics
The possible concerns regarding the safety of probiotics relate to the occurrence 
of disease, such as bacteraemia or endocarditis, toxic or metabolic eﬀ ects on the 
gastrointestinal tract and the transfer of antibiotic resistance in the gastrointestinal 
ﬂ ora (for review, see Snydman, 2008). Although there are rare cases of bacteraemia 
or fungemia related to the use of probiotics, epidemiologic evidence suggests no 
population increase in risk on the basis of usage data (for review, see Snydman, 
2008). For example, increased use of probiotic L. rhamnosus GG in Finland has not 
lead to increase in Lactobacillus bacteraemia (Salminen et al., 2002). L. rhamnosus GG 
has also been given to immunocompromised patients in several clinical studies (e.g. 
preterm and newborn infants, patients with IBD, HIV, cancer, organ transplants) 
without reported adverse eﬀ ects or any case of bacteraemia. Therefore, Lactobacillus, 
Biﬁ dobacterium and Lactococcus strains have generally been regarded as safe (for review, 
see Hammerman et al., 2006; Snydman, 2008). Also the European Food Safety Authority 
(EFSA) has concluded that there are no speciﬁ c safety concerns regarding Lactobacilllus 
and Biﬁ dobacterium or Propionibacterium strains as they have a long history of safe use in 
food. However, it should be taken into consideration that the safety of probiotics has 
not been as systematically investigated as in drugs and the safety evaluation is partly 
based on long term experience only.
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3. Aims of the study
Probiotics have been mostly examined in the prevention and treatment of diﬀ erent 
gastrointestinal diseases and allergies. The ways in which probiotic bacteria elicit 
their health eﬀ ects are not fully understood. One of the most probable mechanisms 
is the immunomodulatory eﬀ ect mediated by the gut mucosal immune system on the 
systemic level. Probiotic products are mainly consumed by healthy people but their 
eﬀ ects on the immune system are poorly understood. The aim of this series of studies 
was to evaluate the ability of probiotics to modulate the immune system in healthy 
adults in randomized, double-blind, placebo-controlled clinical studies as well as in in 
vitro studies.
The speciﬁ c aims were: 
1.  To compare the ability of potentially probiotic bacteria to induce 
cytokine responses in primary cell culture using human peripheral 
blood mononuclear cells (I).
2.  To evaluate whether probiotic intervention has immunomodulatory 
eﬀ ects in healthy adults (II, IV).
3.  To characterize the eﬀ ect of probiotics on global serum lipidomics 
proﬁ les in healthy adults (III).
4.  To investigate whether probiotics are able to reduce the incidence 
of respiratory infections and gastrointestinal symptoms in healthy 
adults (V).
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4. Materials and methods
4.1 Bacterial strains (I)
Eleven potentially probiotic strains or known probiotics used in the study were 
obtained from Valio Research Centre (Helsinki, Finland). Two pathogenic bacterial 
strains, used as controls in the study, were obtained from the collection of the National 
Public Health Institute (Helsinki, Finland). The bacteria were stored in skimmed milk 
at -70°C and passaged three times (except Biﬁ bobacterium strains which were passaged 
four times) prior to use in stimulation experiments. For the stimulation experiments, 
bacteria were grown to logarithmic growth phase, and the number of bacteria was 
determined by counting in a Petroﬀ -Hauser counting chamber. Bacterial strains used 
in this study are presented in Table 10.
4.2 Primary cell culture using peripheral blood mononu-
clear cells
4.2.1 In vitro (I)
In the study I, PBMC were isolated by a Ficoll-Paque density gradient (Amersham-
Pharmacia Biotech, Uppsala, Sweden) from freshly collected, leukocyte-rich buﬀ y coats 
obtained from healthy blood donors (Finnish Red Cross Blood Transfusion Service, 
Helsinki, Finland) (Pirhonen et al., 1999). After washing, the cells were resuspended 
in RPMI-1640 medium (Sigma, St. Louis, Mo., USA) containing 10% heat-inactivated 
foetal calf serum (FCS) with low-endotoxin concentration of 0.7 EU/ml (Integro, 
Zaandam, Holland) and supplemented with 2 mmol/l L-glutamine (Sigma), 100k U/ml 
penicillin and 100 mg/ml streptomycin (Gibco BRL, Paisley, Scotland). Previously, FCS 
from diﬀ erent producers has been tested to evaluate their endotoxin level on cytokine 
induction and Integro’s FCS was selected as it causes the lowest background in cytokine 
analyses. In bacterial stimulation experiments, puriﬁ ed leukocytes (2 x 106 cells/ml) 
were incubated with bacteria in a ﬁ nal volume of 1 ml in 24-well plates (Nunc, Roskilde, 
Denmark) in 5% CO2 at 37°C in RPMI-1640 medium containing 100 ml/l FCS. Live 
bacteria were added into the cell culture to obtain a 10:1 bacteria:host cell ratio. RPMI 
was used as a negative control. When PBMC were stimulated with a combination of two 
bacteria or more, equal numbers of diﬀ erent bacteria were used, and the sum bacterial 
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Strain Abbreviation 
used in the 
study
ATCC or 
DSM number
Culture media Growth 
conditions
Use 
Probiotic
Streptococcus 
thermophilus THS
THS - M17 agar1 with 
lactose2 and M17 
broth3
37°C, aerobic Yoghurt
Lactobacillus 
rhamnosus GG 
LGG ATCC 53103 de Man, Rogosa 
and Sharpe 
(MRS) medium1
37°C, aerobic Probiotic
Lactobacillus 
rhamnosus Lc705 
Lc705 DSM 7061 MRS medium1 37°C, aerobic Probiotic
Lactobacillus 
helveticus 1129
1129 DSM 13137 MRS medium1 42°C, aerobic Cheese, 
fermented 
milk
Lactobacillus 
helveticus Lb 161
161 - MRS medium1 42°C, aerobic Cheese
Bifi dobacterium 
longum 1/10
1/10 - MRS medium1 
with cysteine4
37°C, anaerobic None
Bifi dobacterium animalis 
ssp. lactis Bb12
Bb12 DSM 15954 MRS medium1 
with cysteine4
37°C, anaerobic Probiotic
Bifi dobacterium 
breve Bb99 
Bb99 DSM 13692 MRS medium1 
with cysteine4
37°C, anaerobic Probiotic
Lactococcus lactis ssp. 
cremoris ARH74 
ARH74 DSM 18891 Calciumcitrate 
agar5 and 
M17-broth3 with 
lactose2
22°C, aerobic Finnish viili
Leuconostoc 
mesenteroides ssp. 
cremoris PIA2 
PIA2 DSM 18892 MRS medium1 22°C , aerobic Finnish viili 
Propionibacterium 
freudenreichii ssp. 
shermanii JS 
PJS DSM 7067 Propioni-
medium5
30°C, aerobic Probiotic, 
cheese
Pathogens
Streptococcus pyogenes 
serotype T1M1 
GAS - Sheep blood 
agar6 and 
tryptone-yeast 
broth with 
glucose7 
37°C, aerobic -
Escherichia coli (DH5α) DH5α - Luria-medium8 37°C, aerobic -
1Lab M, Topley House, Lancashire, UK; 2J.T. Baker B.V., Deventer, Holland; 3Difco, Beckton Dickinson, MD, USA; 
4Merck, Darmstadt, Germany; 5Valio Ltd, Helsinki, Finland; 6Oxoid, Ogdensburg, NY, USA; 7(Holm and Falsen, 1967); 
8National Public Health Institute, Helsinki, Finland 
Table 10. Bacteria used in the study.
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Figure 3. Schematic illustration of the primary cell culture using peripheral blood 
mononucealr cells (PBMC).
dose of the combinations was a 10:1 bacteria:host cell ratio. Cell culture supernatants 
were collected from individual donor cell cultures and stored at 20°C before analysis. 
A schematic illustration of the cell culture is presented in Figure 3.
4.2.2 Ex vivo (II)
In study II, PBMCs were isolated from healthy adults before and after the probiotic 
intervention as described in the previous chapter. In stimulation experiments, puriﬁ ed 
leukocytes (2 x 106 cells/ml) were incubated with or without stimulants for 24 h. PBMC 
were left unstimulated or were stimulated with one of three diﬀ erent stimulants; 
a Gram-positive bacterium, a chemical stimulant or a virus. Live Group A streptococci 
S. pyogenes serotype T1M1 was used as a Gram-positive bacterium at 1:1 bacteria:host-
cell ratio; lipopolysaccharide (LPS) from E. coli serotype 0111:B4 (L-3024, Sigma) was used 
as a chemical stimulant at a concentration of 100 ng/ml; and Inﬂ uenza A H3N2 virus 
(A/Beijing/353/89) was used to infect cells at a multiplicity of infection of 5. Cell culture 
supernatants were collected individually at the 24-hour time point and stored at -20°C 
before analysis.
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4.3 Subjects and study designs (II, III, IV, V) 
Studies II and III 
The subjects of studies II and III were healthy adults (n=62). Only the LGG and placebo 
groups of study II were used in study III. The study was a randomised, double-blind, 
placebo-controlled parallel group intervention study carried out in September-January. 
The intervention period was preceded by a three-week run-in period, after which the 
subjects were randomized to receive either a LGG, Bb12, PJS or placebo drink for three 
weeks (Figure 4). After the intervention period, the subjects were followed up for another 
three weeks. Venous blood samples and saliva samples were taken at baseline, day 1, 7 
and 21 and three weeks after the intervention. Faecal samples were collected at home at 
baseline and at the end of the three-week intervention period. The subjects were asked 
to ﬁ ll in a structured symptom diary throughout the whole study. 
Studies IV and V
The subjects of the studies IV and V were healthy, exercising adults who participated 
in the Helsinki City Marathon at the end of the intervention. Studies IV and V 
were conducted as a randomized, double-blind, placebo-controlled parallel group 
intervention studies. The studies were carried out in spring and summer. Prior to 
the intervention period there was a four-week run-in period in April, after which the 
subjects were randomized and stratiﬁ ed according to their personal best marathon time 
to receive either LGG or placebo (Figure 4). The subjects received LGG or placebo for 
three months until the day of the Helsinki City Marathon. The marathon was followed 
by a four-week follow-up period. Venous blood samples were taken at the baseline, 
after the three-month intervention period and on the day of the marathon immediately 
before and after the race. The subjects were asked to ﬁ ll in a structured symptom diary 
and exercise diary throughout the entire study.
A summary of the subjects and interventions is presented in Table 11.
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Figure 4. Schematic presentation of the study designs.
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Study Subjects
Number 
of 
subjects
Gender
Female/
Male
Age, y
Mean 
(Range)
BMI, 
kg/m2
Mean
(Range) Intervention 1
Duration of 
intervention
Main 
endpoints
II Healthy 
adults
62 45/17 44 
(23-58)
24 
(18-30)
Milk-based fruit drink 
(2.5 dl) with 
LGG (1.6 x 1011cfu) 
or 
Bb12 (3.5 x 1011cfu) 
or 
PJS (3.3 x 1011 cfu) 
or without probiotics
3 wk Serum CRP, 
cytokines 
produced 
by cultured 
PBMC, 
serum 
cytokines
III Healthy 
adults
28 15/11 42 
(23-55)
24 
(18-30)
Milk-based fruit drink 
(2.5 dl) with 
LGG (1.6 x 1011cfu) 
or 
without probiotics
3 wk Serum global 
lipidomics 
platform
IV Exercising 
adults
141 16/125 40 
(23-69)
22 
(18-26)
Milk-based fruit drink 
(2 x 65 ml) with 
LGG (3.9 x 1010 cfu) 
or without probiotics
3 mo Serum CRP, 
serum 
cytokines, 
lymphocyte 
subtypes
V Exercising 
adults
141 16/125 40 
(23-69)
22 
(18-26)
Milk-based fruit drink 
(2 x 65 ml) with 
LGG (3.9 x 1010 cfu) 
or without probiotics
3 mo Number of 
healthy days, 
occurrence 
and duration 
of respiratory 
infections and 
GI-symptoms
1 Study products were obtained from Valio Research Centre, Helsinki, Finland. The appearance and taste of the study 
products were identical. 
wk = week, mo = month; LGG = Lactobacillus rhamnosus GG; Bb12 = Bifi dobacterium animalis ssp. lactis Bb12; 
PJS = Propionibacterium freudenreichii ssp. shermanii JS
Table 11. A summary of the subjects and interventions. 
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4.4 Immunological and biochemical measurements 
The immunological and other biochemical parameters determined in the present 
study are summarized in Tables 12 and 13. Detailed descriptions of the measurements 
are available in the original publications. The classiﬁ cation of cytokines into pro/anti-
inﬂ ammatory, Th1/Th2/Treg and chemokines is presented in Table 14.
Variable Method Manufacturer/Reference Study
Acute-phase proteins
Serum highly sensitive 
CRP
Immunoturbidimetric assay by Tina-
quant CRP high-sensitive assay 
reagent (Roche Hitachi 912 analyzer)
Roche Diagnostics GmbH, 
Mannheim, Germany
II, IV
Immune cells
White blood cell counts 
(leukocytes, monocytes, 
neutrophils, basophils and 
lymphocytes)
Electronic counter (Coulter MAXM 
Hematology Analyzer)
Beckman Coulter, Fullerton, 
CA, USA
II, IV
Lymphocyte 
subpopulations: T cells, 
Th cells, cytotoxic T cells, 
B lymphocytes, NK cells
Flow cytometry (FACStar fl ow 
cytometer)
BD Biosciences, San Jose, 
CA, USA
IV
Immunoglobulins
Serum immunoglobulins 
(IgA, IgG and IgM)
Immunoturbidimetric method with 
Tina-quant Roche/Hitachi System 
reagent (Roche Hitachi 912 analyzer)
Roche Diagnostics GmbH, 
Mannheim, Germany
II
Saliva secretory IgA ELISA Gentaur, Brussels, Belgium II
Cytokines
Gene expression of 
TNF-α, IL-12p40, IL-
12p35, IFN-γ and IL-10 
Northern Blotting (Miettinen et al., 1998) I
In vitro production of 
cytokines in PBMC 
culture (TNF-α, IL-10, 
IFN-γ, IL-12p70)
ELISA BD Pharmingen, San Diego, 
CA, USA (TNF-α, IL-10) 
BioSite, Täby, Sweden (IFN-γ, 
IL-12p70)
I
Ex vivo production of 
cytokines in PBMC 
culture (TNF-α, IFN-γ, 
IL-1β, Il-2, IL-4, IL-5, IL-6, 
IL-8, IL-10 and IL-12p70)
Multiplex Fluorescent Bead 
Immunoassay (FlowCytomix human 
Th1/Th2 10plex kit II)
Bender MedSystems, Vienna, 
Austria
II
Serum cytokine levels 
(TNF-α, IL-6, IFN-γ and 
IL-10)
ELISA (Quantikine high sensitive 
immunoassays)
R&D Systems, Minneapolis, MN, 
USA
II, IV
Serum chemokine levels 
MCP-1 (CCL2) and IP-10 
(CXCL10)
ELISA BD Pharmingen, San Diego, 
CA, USA
IV
Table 12. Immunological measurements carried out in the study.
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Variable Method Manufacturer/Reference Study
Haematology
Erythrocytes, 
haemoglobin, 
haematocrit, MCV, MCH, 
MCHC, thrombocytes
Electronic counter (Coulter MAXM 
hematology analyzer)
Beckman Coulter, Fullerton, CA, 
USA
V
Serum lipids
Total cholesterol, 
high-density lipoprotein 
(HDL) cholesterol and 
triglycerides
Autoanalyser (Roche/Hitachi 912 
Automatic Analyzer)
Roche Diagnostics GmbH, 
Mannheim, Germany
III
Serum low-density 
lipoprotein (LDL) 
cholesterol
Calculation using Friedewald’s 
equation
(Friedewald et al., 1972) III
Hormones
Serum cortisol Luminoimmunoassay (VITROS ECi 
analyser)
Ortho-Clinical Diagnostics, 
Amersham, UK 
IV
Serum prolactin Immunometric assay Diagnostic Products Corporation, 
Los Angeles, CA, USA
IV
Serum testosterone Electrochemiluminescence 
immunoassay
Testosterone, Roche Diagnostics 
GmbH, Mannheim, Germany
IV
Table 13. Biochemical measurements carried out in the study.
Table 14. Classiﬁ cation of the cytokines measured in the study.
Cytokine Pro-
infl ammatory
Anti-
infl ammatory
Th1 Th2 Treg Chemokine
TNF-α x
IL-1β x
IL-6 x x
IFN-γ x x
IL-2 x
IL-12 x
IL-4 x
IL-5 x
IL-10 x x
CCL2 x x
CXCL8 x x
CXCL10 x x
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4.5 Global serum lipidomics proﬁ ling (III)
In the study III in healthy adults the global lipidomics platform based on Ultra 
Performance Liquid Chromatography (UPLC) coupled to high resolution mass 
spectrometry (MS) was utilized. The applied platform aﬀ ords broad screening of multiple 
lipid classes from total lipid extracts within a single sample run (major monoacylglycerols 
and phospholipids, diacylglycerols and diacylglycero-phospholipids, sphingolipids, 
triacylgycerols and cholesterol esters). The lipid proﬁ ling was carried out on Waters 
Q-Tof Premier mass spectrometer. Data were processed using MZmine software 
version 0.60 (Katajamaa et al., 2006). Lipids were identiﬁ ed using internal spectral 
library or with tandem mass spectrometry (Yetukuri et al., 2007). The normalization of 
lipidomics data was performed as follows: all monoacyl lipids except cholesterol esters, 
such as monoacylglycerols and monoacylglycero-phospholipids were normalized with 
GPCho(17:0/0:0), all diacyl lipids except ethanolamine phospholipids were normalized 
with GPCho(17:0/17:0), ceramides with Cer(d18:1/17:0), the diacyl ethanolamine 
phospholipids were normalized with GPEtn(17:0/17:0), and the triacylglycerols and 
cholesterol esters with TG(17:0/17:0/17:0). Other (unidentiﬁ ed) molecular species were 
calibrated with GPCho(17:0/0:0) for retention time < 300 seconds, GPCho(17:0/17:0) for 
retention time between 300s and 410s, and TG(17:0/17:0/17:0) for higher retention times. 
Lipids from the lipidomic analysis were named according to Lipid Maps (http://www.
lipidmaps.org). 
4.6 Questionnaires (II, V)
Symptom diary 
The subjects of studies II and V were asked to ﬁ ll in a symptom diary with ready-made 
questions throughout the study. Each day the subjects rated their health status (healthy 
or sick) and recorded whether they had had any upper respiratory tract infection 
symptoms (fever, rhinitis, sore throat, cough, wheezing, earache), gastrointestinal 
symptoms (diarrhoea, vomiting, stomach ache) or any other symptoms or medication 
during the day. Subjects were considered to have a respiratory tract infection if they 
suﬀ ered from any respiratory tract infection symptoms for at least two consecutive days 
and if the next respiratory tract infection symptoms appeared only after three or more 
days; otherwise they were considered to be suﬀ ering from the same respiratory tract 
infection. The criterion for an episode of gastrointestinal symptoms was a duration of at 
least one day and at least three days before the next gastrointestinal symptom appeared. 
In the study V in exercising adults, the incidence and duration of respiratory tract 
– 66 –
infections and gastrointestinal symptom episodes were the main outcome measures 
while the purpose of the study diary in the study II in healthy adults was to monitor 
that the health status of the subjects remained the same throughout the study and that 
falling ill would not aﬀ ect the immunological measurements. The symptom diary was 
not systematically validated, but it has been used in previous studies by our group.
Exercise diary
In the study II in healthy adults, the study diary included a question about the amount 
of exercise daily. In studies IV and V, the exercising adults were asked to keep a separate 
daily exercise diary in which they reported their running distance in kilometres and 
minutes and other exercise in minutes.
4.7 Compliance to the probiotic interventions
Consumption of probiotic products (II, III, IV, V)
In studies II, III, IV and V, the subjects recorded the consumption of the study products 
in the study diary daily.
Measuring probiotics from faecal samples (II) 
In study II, faecal samples were taken to examine the recovery of probiotics in faeces 
in order to conﬁ rm compliance. Samples were collected at home at baseline and at the 
end of the three-week intervention period. The subjects were asked to put the samples 
into the deep-freeze (-20°C) at home immediately after collection. The samples were 
subsequently transported to the study centre on the morning of the study day where 
they were immediately refrigerated and stored at -70°C until analysis. The amounts of 
the probiotic strains LGG, Bb12 and PJS in the faecal samples were analysed with real-
time quantitative PRC as previously described (Myllyluoma et al., 2007).  
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4.8 Statistical analysis 
The statistical analyses in studies II, IV and V were performed using SPSS version 14.0 
software (SPSS Inc, Chicago, IL, USA) or STATA version 9.1 software (StataCorp, Texas, 
USA). All outcome analyses were performed by intention to treat (ITT). The results are 
expressed as mean with standard deviation (SD) or a 95 percent conﬁ dence interval 
(95% CI) or as medians with interquartile range (IQR). 
In study II, the responses for the outcomes were calculated as the area under the 
curve from days 0, 1, 7 and 21, subtracted by the baseline value (AUC0-21 minus baseline). 
The diﬀ erences between the groups were compared using either the Kruskal-Wallis 
test or median regression analysis with Holm’s adjustment for pairwise comparisons. 
These nonparametric methods were adopted because of skewed distributions. The 
95% conﬁ dence intervals for Spearman’s correlation coeﬃ  cients were obtained by bias-
corrected bootstrapping (5000 replications). 
In study IV, the change to the end of intervention was estimated using either mean 
change or Hodges-Lehman estimate for median shift. The conﬁ dence intervals for 
changes were obtained by bootstrapping. Statistical comparisons between groups were 
performed using bootstrapped-type analysis of covariance (ANCOVA) with the baseline 
value as the covariate. These methods were used due to the violations of parametric 
assumptions. Analysis of covariance for cytokines was done by median regression with 
baseline value as a covariate.
In study V, a continuous statistical comparison between the groups was made using 
the t-test, ANCOVA or Mann-Whitney test (with Monte Carlo p-value). Measures with a 
discrete distribution were analyzed using the Chi-Square or Fischer’s exact test and are 
expressed as counts (%).
In study III, principal components analysis (PCA) and partial least squares 
discriminant analysis (PLS/DA) with log-transformed values were utilized as modelling 
methods for clustering and discrimination (Barker and Rayens, 2003). The VIP (variable 
importance in the projection) values (Wold, 1987) were calculated to identify the most 
important molecular species for the clustering of speciﬁ c groups. Comparisons 
between the levels of selected molecular species were performed using the paired 
Wilcoxon test. A change detection plot was used to account for multiple hypothesis 
testing in univariate comparisons. In order to asses whether any of the clinical variables 
are explained by lipidomics proﬁ le data, the lipidomics proﬁ le data was regressed on 
selected clinical variables using the elastic net method (Zou, 2005). PLS/DA and PCA 
analyses were performed using Matlab version 7.2 (Mathworks, Natick, MA, USA), PLS 
Toolbox version 4.0 Matlab package (Eigenvector Research, Wenatchee, WA, USA). All 
other analyses were performed using the R statistical language (http://www.r-project.
org/). 
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4.9 Ethics
The ethical permission to use freshly collected, leukocyte-rich buﬀ y coats obtained 
from healthy blood donors (Finnish Red Cross Blood Transfusion Service, Helsinki, 
Finland) in the study I was given by the ethics committee of the Finnish Red Cross 
Blood Transfusion Service in Helsinki. All clinical studies were carried out according 
to the ethical principles of the Declaration of Helsinki and Good Clinical Practice. The 
study protocols of the clinical interventions were approved by the Ethics Committee of 
the Hospital District of Helsinki and Uusimaa. Before entering the study, the subjects 
gave their informed consent. 
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5. Results
5.1 Cytokine responses in peripheral blood mononuclear 
cells in vitro (I)
The ability of known and potentially probiotic bacterial strains and their combinations 
to induce cytokine responses was studied in in vitro cultured human PBMC. The optimal 
dose (10:1 bacteria:host cell) and stimulation time were selected based on dose-response 
and kinetics experiments. Probiotics were found able to direct immune responses to 
either cell-mediated (Th1) or anti-inﬂ ammatory (Treg) direction in a genera-speciﬁ c 
manner. All tested bacteria induced TNF-α production. The best inducers of Th1-type 
cytokines IL-12 and IFN-γ were THS and PIA2, being also more potent inducers of these 
cytokines than the probiotic LGG and Lc705 strains presently in use. All Biﬁ dobacterium 
strains (Bb12, Bb99 and 1/10) as well as PJS induced the highest anti-inﬂ ammatory IL-10 
production. 
The probiotic bacteria and their combinations which have been used in previous 
clinical trials, namely combinations of LGG, Lc705, PJS and Bb99 or Bb12 and a 
combination of LGG, Lc705 and PJS, were used to study whether the eﬀ ect of probiotic 
combinations diﬀ ers from an individual strain. In addition, the representatives of the 
best cytokine inducers, namely THS, Bb12, Bb99, 1/10, PIA2 and PJS as well as LGG 
as a reference bacterium, were analysed for their possible additive and synergistic 
eﬀ ects on cytokine production. Stimulation of PBMC with any bacterial combinations 
did not result in enhanced cytokine production. Instead, the responses induced by 
the combinations were closer to an average of responses induced by the individual 
bacteria suggesting that diﬀ erent bacteria compete with each other during host cell 
interactions. 
The probiotic bacteria were selected to the clinical studies based on their anti-
inﬂ ammatory potential. The ability to induce high IL-10 (anti-inﬂ ammatory cytokine) 
and low IL-12 (Th1-type cytokine) production was used for the classiﬁ cation of strains 
to “anti-inﬂ ammatory and Th1-type strains” (Figure 5.) The highest producers of 
IL-10, being also the lowest producers of IL-12, were thus selected for further clinical 
studies. The strains selected for further studies were Bb12 and PJS due to their anti-
inﬂ ammatory capacity and LGG as a well-documented reference probiotic. 
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Figure 5. Production of IL-10 and IL-12 by peripheral blood mononuclear cells after 
24h stimulation by diﬀ erent bacteria (10:1 bacteria:host-cell ratio). The bars represent 
the mean and SEM (pg/ml) of 16 blood donors.
5.2 Immunomodulatory effects of probiotics in healthy 
adults in clinical studies (II, IV)
5.2.1 Serum CRP (II, IV)
In order to study the eﬀ ect of probiotics on the inﬂ ammatory status of the subjects, 
the serum highly sensitive CRP levels were measured in studies II and IV. In study II 
carried out in healthy adults, CRP (median AUC0-21 minus baseline) was -0.240 mg/l 
in LGG, -0.085 mg/l in PJS, 0.090 mg/l in Bb12 and 0.018 mg/l in the placebo group 
(p=0.014 between groups); a statistically signiﬁ cant diﬀ erence was observed between the 
LGG and Bb12 groups by pairwise comparisons. CRP appeared to be at a lower level in 
the LGG and PJS groups during the intervention (Figure 6). In study IV in exercising 
adults, the mean change in serum CRP levels after the three-month intervention period 
was -0.48 mg/l in the LGG group and 0.52 mg/l in the placebo group (p=0.20). 
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Figure 6. The median AUC0-21 (minus baseline) with IQR for serum highly sensi-
tive CRP (hsCRP) levels during the three-week intervention period in healthy adults 
in study II (n=16 in placebo, n=13 in LGG, n=16 in Bb12 and n=17 in PJS group). 
LGG = Lactobacillus rhamnosus GG; Bb12 = Biﬁ dobacterium animalis ssp. lactis Bb12; 
PJS = Propionibacterium freudenreichii ssp. shermanii JS
5.2.2 Serum cytokines (II, IV)
The serum IL-6 concentration was lower in the LGG group versus the placebo group 
after the three-month intervention in study IV in exercising adults (p=0.041). No 
diﬀ erences between the groups were observed in the serum TNF-α or chemokine 
(MCP-1, IP-10) levels. In study II in healthy adults, there were no diﬀ erences between 
the study groups in serum cytokines during the three-week intervention. Nearly all 
samples of serum IFN-γ and IL-10 were under the detection limit in both studies and 
therefore no further analysis was made. 
5.2.3 Cytokine responses in peripheral blood mononuclear cells ex vivo (II)
In study II in healthy adults, the cytokine production by ex vivo isolated, stimulated 
(Streptococcus pyogenes, Inﬂ uenza A virus, LPS) PBMC was determined as a measurement 
reﬂ ecting the functional responses of cells of both innate and adaptive immunity (PBMC 
consists of monocytes, NK cells, T and B cells). S. pyogenes-stimulated production of 
proinﬂ ammatory cytokine TNF-α diﬀ ered between the groups (p=0.025), reaching the 
lowest level in subjects receiving LGG during the three-week intervention (Figure 7.). 
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Statistically signiﬁ cant diﬀ erence was observed between LGG and placebo group by 
pairwise comparisons. Also Inﬂ uenza A virus-stimulated production of Th1 associated, 
proinﬂ ammatory cytokine IL-2 was signiﬁ cantly diﬀ erent between the groups (p<0.001), 
being at its lowest in the Bb12 group during the intervention (Figure 7.). There were no 
signiﬁ cant diﬀ erences between the study groups with respect to the other measured 
cytokines (IL-1β, IL-6, IFN-γ, IL-12p70, IL-8, IL-10). IL-4 and IL-5 were not analysed 
since less than 80% of the samples exceeded the detection limit. 
Figure 7. The median of the area under curve (AUC0-21 minus baseline) with interquartile 
range for Streptococcus pyogenes (GAS) -stimulated TNF-α production (left) and Inﬂ uenza 
A virus-stimulated IL-2 production (right) after 24h stimulation by peripheral blood 
mononuclear cells during the three-week intervention period in healthy adults (n=16 
in placebo, n=13 in LGG, n=16 in Bb12 and n=17 in PJS group). LGG = Lactobacillus 
rhamnosus GG; Bb12 = Biﬁ dobacterium animalis ssp. lactis Bb12; PJS = Propionibacterium 
freudenreichii ssp. shermanii JS
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5.2.4 Ratio between IL-10 and IL-12 produced by peripheral blood 
mononuclear cells ex vivo (unpublished)
As the classiﬁ cation of the probiotic strains to “anti-inﬂ ammatory and Th1-type strains” 
in study I in vitro was based on the IL-10 and IL-12 production and the selection of 
strains to study II in healthy adults was premised on this assumption, the ratio between 
IL-10 and IL-12 was calculated from the cytokines produced by the ex vivo isolated 
PBMC in study II in healthy adults. Here the high versus low IL-10/IL-12 ratio exhibits 
an “anti-inﬂ ammatory” versus “Th1-type” proﬁ le, respectively. The mean value of IL-10/
IL-12 ratio was four-fold after the LGG intervention when PBMC were stimulated with 
S. pyogenes (p=0.16 between groups at day 21) (Figure 8.). The ratios between IL-10 and 
IL-12 in inﬂ uenza A virus and LPS-stimulated PBMC before and after the intervention 
are presented in Figure 8 (p=0.80 and p=0.85 between groups at day 21, respectively).
Figure 8. The ratio between IL-10 and IL-12 measured from the supernatants of 
ex vivo isolated, stimulated (Streptococcus pyogenes, Inﬂ uenza A virus, LPS) peripheral 
blood mononuclear cells at baseline (open bars) and at the end of the three-week 
intervention (ﬁ lled bars) represented as mean. LGG = Lactobacillus rhamnosus GG; 
Bb12 = Biﬁ dobacterium animalis ssp. lactis Bb12; PJS = Propionibacterium freudenreichii 
ssp. shermanii JS
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5.2.5 Correlation between serum cytokine levels and cytokines produced by 
peripheral blood mononuclear cells ex vivo (unpublished)
In order to evaluate whether serum cytokine levels and cytokine production by 
unstimulated and stimulated PBMC ex vivo correlate with each other, Spearman’s 
correlation coeﬃ  cient was determined from the baseline samples of study II in healthy 
adults. There was no statistically signiﬁ cant correlation between serum cytokine levels 
and cytokines produced in stimulated PBMCs. The correlation between serum TNF-α 
and TNF-α produced by unstimulated and LPS-stimulated PBMC is presented in 
Figure 9 and for IL-6 in Figure 10. Correlation coeﬃ  cients between cytokines induced 
by S. pyogenes and inﬂ uenza A virus -stimulated PBMC and serum cytokines varied 
from 0.02 to 0.04.
Figure 9. Scatter plots with Spearman’s correlation coeﬃ  cient between serum TNF-α 
and TNF-α produced by unstimulated (left) and LPS-stimulated (right) PBMC ex vivo at 
baseline in healthy adults (n=62).
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Figure 10. Scatter plots with Spearman’s correlation coeﬃ  cient between serum IL-6 
and IL-6 produced by unstimulated (left) and LPS-stimulated (right) PBMC ex vivo at 
baseline in healthy adults (n=62).
5.2.6 Leukocytes, lymphocyte subtypes and immunoglobulins (II, IV)
In study IV in exercising adults, the number of monocytes in serum was lower in the 
LGG group versus placebo after the three-month intervention (p=0.041). However, in 
the shorter three-week intervention in healthy adults (study II), no diﬀ erences in the 
number of monocytes were observed. In studies II and IV, there were no diﬀ erences in 
the total leukocyte counts or in the major leukocyte subtype distribution (neutrophils, 
basophils, eosinophils, lymphocytes) between the study groups. In study IV, the major 
lymphocyte subsets (CD3+ T cells, CD4+ helper T cells, CD8+ cytotoxic T cells, CD19+ 
B cells, CD16+CD56+ NK cells) remained unchanged after the intervention. Also the 
serum immunoglobulin levels (IgA, IgG, IgM) remained unchanged during the three-
week intervention in study II. The secretory IgA in saliva was measured in study II in 
healthy adults but no diﬀ erences between the study groups were detected during the 
three-week intervention. 
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5.3 Global serum lipidomics proﬁ les (III)
As LGG seemed to exhibit the best anti-inﬂ ammatory potential in study II in healthy 
adults, the LGG and placebo groups of study II were used for investigating the eﬀ ect of 
probiotics on lipid-derived mediators in study III. For this purpose, global lipidomics 
proﬁ les in serum were determined. A total of 407 lipids falling into 13 diﬀ erent lipid 
classes were identiﬁ ed. In the principal component analysis, no major outliers exist in the 
data. Partial least squares discriminant analysis on the log-transformed data indicated 
that the groups are separable (Figure 11a.) The analysis also revealed that the LGG and 
placebo groups diﬀ ered at the baseline and therefore only within-person changes were 
used in further analyses. As the within-person changes before and after intervention 
were compared using the paired Wilcoxon test, six lipids [triacylglycerol TAG(55:3); 
sphingomyelin SM(d18:1/24:2); lysoglycerophosphatidylcholine LysoGPCho(18:2); 
glycerophosphoserine GPSer(36:1); glycerophosphoethanolamine GPEtn(44:6e); 
glycerophosphocholine GPCho(38:7)] were found to change signiﬁ cantly (Figure 11b). 
Based on multiple hypothesis testing using the change detection plot, no lipid changes 
were found signiﬁ cant within the 95% conﬁ dence interval. One thus cannot exclude 
the possibility of some of the signiﬁ cant changes being detected by chance. However, 
some common trends were observed; triacylglycerols and glycerophosphocholines 
increased mainly in the LGG intervention group, while several of the proinﬂ ammatory 
lysophosphatidylcholines and sphingomyelins decreased.
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B
Figure 11. A. Partial least squares discriminant analysis (PLS/DA) of serum lipidomic 
data. The labels are subject ID numbers. B. Fold changes for the top 30 ranking lipids 
contributing to the PLS/DA model based on variable important in the projection 
analysis (VIP) (* p<0.05, *** p<0.001). LGG = Lactobacillus rhamnosus GG
A
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5.4 Clinical outcome (V)
In addition to diﬀ erent immunological measurements, the incidence and duration of 
respiratory infections and gastrointestinal symptom episodes were measured by a daily 
symptom diary in study V in exercising adults. The mean number of healthy days, i.e. 
days without any symptoms of respiratory infection or gastrointestinal symptoms was 
79 in the LGG group and 73 in the placebo group during the three-month training 
period before the marathon (p=0.82). 
Respiratory infections
There were no diﬀ erences between the LGG and placebo groups in the number and 
duration of respiratory infections during the three-month probiotic intervention 
period before the marathon or two weeks immediately after the marathon.
Gastrointestinal symptom episodes
During the three-month probiotic intervention period before the marathon and 
two weeks after the marathon, no diﬀ erences between groups in the number of 
gastrointestinal symptom episodes were detected. However, during the two-week 
follow-up after the marathon, the duration of the gastrointestinal symptom episodes 
was shorter in the LGG group than in the placebo group (1.0 vs. 2.3 days, p=0.046). 
During the three-month probiotic intervention period before the marathon, the 
duration of the gastrointestinal symptom episodes was 2.9 days in the LGG group and 
4.3 days in the placebo group (p=0.35).
Exercise habits and serum hormones reﬂ ecting exercise-induced stress
In study V, subjects in the LGG group exercised (running and other forms of 
exercise) more often than those in the placebo group during the training period (4.8 
vs. 4.4 times weekly, p=0.024). The higher exercise rate of the LGG group during the 
intervention may also have been reﬂ ected as a higher serum cortisol level at the end 
of the intervention compared to the placebo group (p=0.011). However, the levels 
of the other measured stress hormones, testosterone and prolactin, remained the 
same at the end of the intervention (p=0.25 and p=0.22, respectively) (unpublished) 
(Table 15).
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5.5 Compliance and recovery of probiotic strains 
in faeces (II-V)
According to the self-reported consumption of study products based on daily diaries, 
compliance was good in all studies. Indicated by the received study diariesin studies II 
and III in healthy adults, the self-reported mean consumption (SD) of LGG was 20.9 (0.3) 
days, of Bb12 20.4 (1.8) days, of PJS 20.1 (2.0) days and of placebo 20.6 (1.0) days (p=0.60). In 
studies IV and V in exercising adults, the self-reported mean consumption of LGG was 
84/89 days and of placebo 76/89 days (p=0.93).
In study II in healthy adults, the recovery of probiotic strains in faeces was measured 
in order to conﬁ rm the compliance. The baseline bacterial DNA levels for all three 
studied probiotics were low in the faecal samples. Despite the three-week run-in period 
with probiotic restriction, a detectable level of the probiotic strains, especially LGG, was 
harboured in some of the subjects at baseline before the probiotic intervention period. 
The amount of studied probiotic strains in faeces in a given probiotic intervention 
group increased signiﬁ cantly from the baseline values during the intervention (p<0.001). 
In the placebo group, the levels of probiotics in faeces remained low during the whole 
intervention period.
Hormone
Baseline Change to the end of intervention P-value 
between 
groups 1
Placebo
Mean (SD)
LGG
Mean (SD)
Placebo
Mean (95 % CI)
LGG
Mean (95 % CI)
Cortisol 378 (89) 404 (107) -7 (-31 to 16) 24 (-2 to 49) 0.011
Testosterone 18 (7) 16 (8) -0.2 (-1.4 to 0.9) 0.7 (-0.4 to 1.8) 0.25
Prolactin 183 (113) 185 (118) 1.3 (-20.7 to 23.3) 19.6 (-1.7 to 40.8) 0.22
1Bootstrap type analysis of covariance.
Table 15. The mean change in hormones (nmol/l) reﬂ ecting exercise-induced stress 
during a three-month intervention in study V in exercising adults.
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6. Discussion
It is not fully understood how probiotics exert their beneﬁ cial eﬀ ects on health, but one 
of the most probable mechanisms of action is the modulation of immune responses 
via the mucosal immune system of the gut. Most of the research on probiotics has 
concentrated on the prevention and treatment of gastrointestinal diseases and 
allergy. Probiotic products, however, are usually consumed by the healthy population 
but not much is known on their immunomodulatory eﬀ ects in healthy adults. This 
study investigated the immunomodulatory properties of probiotics by systematical 
screening in primary cell culture using human PBMC and evaluated the eﬀ ects of the 
most eﬀ ective probiotic strains on the immune system of healthy adults in randomized, 
double-blind, placebo-controlled clinical trials. In addition, novel lipidomics proﬁ ling 
was performed to characterize the eﬀ ect of probiotics on lipid-derived mediators. 
6.1 Methodological aspects
6.1.1 Selection of strains
Bacteria from diﬀ erent genera (Lactobacillus, Biﬁ dobacterium, Propionibacterium, 
Streptococcus, Lactococcus, Leuconostoc) and diﬀ erent species from a given genera were 
selected for the screening of immunomodulatory eﬀ ects. L. rhamnosus GG (LGG) 
(Saxelin et al., 2005) and B. animalis ssp. lactis Bb12 (Bb12) (Salminen et al., 2006) are 
widely used and studied probiotics in Europe. However, not much is known on how 
these strains aﬀ ect the immune system of a healthy individual. The combination of 
LGG, L. rhamnosus Lc705 (Lc705), P. freudenreichii ssp. shermanii JS (PJS) and B. breve Bb99 
(Bb99) or Bb12 has ameliorated the symptoms of irritable bowel syndrome (Kajander et 
al., 2005; Kajander et al., 2008), reduced the side-eﬀ ects of Helicobacter pylori treatment 
(Myllyluoma et al., 2005) and the probiotic combination with and without prebiotic 
galacto-oligosaccharides has prevented atopic eczema (Kukkonen et al., 2007; Viljanen 
et al., 2005c). The possible immunomodulatory eﬀ ects of these individual strains or 
a combination thereof have not been fully elucidated, although there is some data 
suggesting that the probiotic combination modulates the immune system diﬀ erently 
in allergic children compared to LGG alone (Pohjavuori et al., 2004; Viljanen et al., 
2005b). L. helveticus Lb 161 (161) (Staaf et al., 2000), L. helveticus 1129 (1129) (Yang et 
al., 2000), Lc. lactis ssp. cremoris ARH74 (ARH74) (Yang et al., 1999) and S. thermophilus 
THS (THS) (Nordmark et al., 2005) have been studied due to their exopolysaccharide 
producing characteristics, but no data on the immunomodulatory eﬀ ects of these 
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strains is available. The health eﬀ ects of B. longum 1/10 (1/10) isolated from faeces of 
healthy infants and Ln. mesenteroides ssp. cremoris PIA2 (PIA2) used in the production of 
Finnish viili have not been previously studied. 
The anti-inﬂ ammatory potential of the strains in the primary cell culture using 
PBMC was used as a basis for the selection of strains for clinical studies in healthy 
adults. The anti-inﬂ ammatory potential was determined as high IL-10 and low IL-12 
production. The IL-10/IL-12 ratio has been used to characterize the anti-inﬂ ammatory 
eﬀ ects in previously conducted probiotic (Foligne et al., 2007; O'Mahony et al., 2005), 
virological (Arvå and Andersson, 1999; Feng et al., 2003; Gurney et al., 2005; Legg et al., 
2003) and other immunological studies (Emmer et al., 2006; Itoh et al., 2002; Koopman 
et al., 2003; Townsend et al., 2007). In addition to the most eﬀ ective anti-inﬂ ammatory 
strains Bb12 and PJS, LGG was selected for further studies as a well-documented 
reference probiotic (for review, see Saxelin et al., 2005). 
6.1.2 Primary cell culture model using human peripheral blood 
mononuclear cells
Human PBMC were used as a screening model for the immunomodulatory eﬀ ects 
of probiotic strains. The protein production and mRNA expression of representative 
examples of proinﬂ ammatory (TNF-α), Th1-type (IFN-γ, IL-12) and anti-inﬂ ammatory 
(IL-10) cytokines were analyzed. Mononuclear cells consist of monocytes, NK cells, T 
cells and B cells, which are most likely not in direct contact with probiotics in the actual 
in vivo situation in the human gut. The probiotic-host interaction takes place on the 
gut epithelial cells. However, probiotics may be taken up for example by macrophages 
(Sun et al., 2007) and presented to T and B lymphocytes, leading to their activation in 
Peyer’s patches (for review, see McCracken and Lorenz, 2001). As in vitro cell models 
are very artiﬁ cial in the sense that they lack interaction with other cells, PBMC may 
be a better model compared to single cell cultures, such as macrophages or dendritic 
cells, because PBMC comprise many types of cells. Indeed, PBMC have been extensively 
used for studying and screening the eﬀ ects of probiotics on cytokine production 
(Castanheira et al., 2007; Castellazzi et al., 2007; Drouault-Holowacz et al., 2006; Foligne 
et al., 2007; Gackowska et al., 2006; Haller et al., 2000; Helwig et al., 2006; Hessle et al., 
1999; Lammers et al., 2003; Medina et al., 2007; Miettinen et al., 1998; Miettinen et al., 
1996; Niers et al., 2005; O'Mahony et al., 2006; Pochard et al., 2002; Rasche et al., 2007; 
Shida et al., 2006b; Timmerman et al., 2007). 
Validation and standardisation of the conditions of cell culture is an important 
factor aﬀ ecting the results. The growth conditions (media, temperature, atmosphere) as 
well as the optimal bacteria:host cell ratio in the cell culture are critical to the results. 
The optimal ratio was determined by dose-response experiments in the beginning of 
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the study, and the diﬀ erences in the kinetics of the chosen cytokines were taken into 
account by choosing several timepoints in the experiments. 
6.1.3 Subjects
The subjects were considered to represent the general, healthy adult population without 
any major chronic diseases. Healthy adults participating in a marathon were used as 
a sensitized model to study infections as hard-training individuals are known to be 
more prone to respiratory infections and the risk of infections is particularly high after 
competitive events (for review, see Gleeson, 2007). Because strenuous exercise is also 
known to cause many gastrointestinal symptoms such as vomiting, nausea, diarrhoea 
and heartburn (Peters et al., 2001; Simons and Kennedy, 2004), adults participating 
in a marathon comprised a good model for evaluating the eﬀ ect of probiotics on the 
reduction of gastrointestinal symptoms. 
6.1.4 Designs of intervention studies
The clinical intervention studies were carried out in randomized, double-blind and 
placebo-controlled settings. The sample size of the studies was rather small. The 
required sample size for the studies was not calculated as the a priori information was 
not available. All recruited subjects who fulﬁ lled the inclusion criteria, were included 
in these studies and therefore the largest possible subject material was used.
A suﬃ  ciently long run-in period is an important factor in clinical interventions. 
In previous studies, probiotics were detected in faeces after a two-week run-in period 
(Alander et al., 1999; Myllyluoma et al., 2007; Suomalainen et al., 2008). A three-week 
run-in period with a restriction to use any probiotic products was therefore used in 
studies II and III. However, even this period of time may not have been suﬃ  ciently 
long as detectable, albeit very low levels of studied probiotics were found in the 
baseline samples in study II. These results indicate a need for suﬃ  ciently long run-in 
and follow-up periods in probiotic interventions. Consequently, the run-in period of 
studies IV and V was set to four weeks.
The immunomodulatory eﬀ ects were studied both in the short three-week 
intervention and in the longer three-month intervention. The optimal length of 
intervention for the investigation of diﬀ erent immune measures is diﬃ  cult to 
determine. In the short three-week intervention, also the acute eﬀ ects were taken into 
account by several measurement timepoints (day 0, 1, 7, 21 and in addition day 42 as a 
follow-up sample). In addition to the markers of immunomodulation, the incidence 
of respiratory infections and gastrointestinal symptoms were studied in the longer, 
three-month intervention. The length of the previous studies investigating the eﬀ ect 
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of probiotics and respiratory infections have varied a lot, ranging from three weeks 
(Turchet et al., 2003) to approximately three months (de Vrese et al., 2005b; de Vrese et 
al., 2006; Tubelius et al., 2005; Weizman et al., 2005; Winkler et al., 2005) while the longest 
interventions have lasted from six to seven months (Hatakka et al., 2007; Hatakka et al., 
2001). 
The probiotics were given in milk-based fruit-drinks and the taste and appearance 
of the probiotic and placebo products were identical. The viability of probiotic bacteria 
were measured from each study product batch immediately after manufacture and on 
the best before date (three weeks from manufacture). The adherence to the probiotic 
interventions was good reﬂ ecting a high motivation of the subjects. Compliance was 
measured by the self-reported consumption of study products by means of a study 
diary and also by measuring the ingested probiotic strains from faeces. 
6.1.5 Immunological and biochemical measurements 
In studies investigating the eﬀ ect of nutritional intervention on measurements of 
immune function, it is critical to ensure that the subjects do not fall ill during the 
intervention (for review, see Albers et al., 2005). In the short-term three-week intervention, 
this was taken into account by means of daily study symptom diaries which revealed 
the subjects having no respiratory or other infections during the intervention period. 
There is no single marker to study the eﬀ ect of nutrition intervention on the immune 
function (for review, see Albers et al., 2005; Calder and Kew, 2002; Cummings et al., 
2004). Therefore, to gain a comprehensive understanding of the immune function a 
combination of measures of the basal status of the immune system, gut-associated 
markers and ex vivo measurements reﬂ ecting the functional capacity of cells of innate 
and adaptive immunity were selected as parameters in this thesis. To gain a broad 
picture on the eﬀ ect of studied probiotics on cytokine production, a wide selection 
of cytokines with representatives of pro- (TNF-α, IL-1β, IL-6) and anti-inﬂ ammatory 
cytokines (IL-10) as well as Th1 (IL-2, IFN-γ, IL-12) and Th2-type cytokines (IL-4, IL-5) 
and chemokines (CXCL8, CXCL10, CCL2), was used. In addition, well-established 
immunological methods, including novel lipidomics proﬁ ling analysis using UPLC/
MS technique, were applied. Lipidomics is a rapidly evolving branch of metabolomics 
(Schnackenberg and Beger, 2006; Wiest and Watkins, 2007) which enables the functional 
characterization of endogenous lipid metabolites. However, the results should be 
interpreted with caution as it is not yet known how the changes in lipid metabolites are 
associated with the individual metabolic health or major metabolic and inﬂ ammatory 
diseases.
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6.1.6 Questionnaires
Infections can be measured either by self-reported study diaries or by diagnoses made 
by physician. There is no exact deﬁ nition for a respiratory infection. Furthermore, the 
deﬁ nitions vary from one study to another ranging from one symptomatic day (de 
Vrese et al., 2005b; de Vrese et al., 2006) to symptoms on at least two consecutive days 
(Tiollier et al., 2007), and these studies fail to deﬁ ne what is considered as a separate 
infection. A relatively widely used deﬁ nition for the separation of two infection episodes 
is a symptom-free period of at least three days in between (Uhari and Möttönen, 1999) 
which was adopted also in the present study. The symptom diary used in this study 
was not systematically validated, but it has been used in previous studies by our group. 
Respiratory infections were recorded in a subjective daily symptom diary with ready-
made questions that has already been used in previous studies by our group in children 
(Hatakka et al., 2007; Hatakka et al., 2001) and the elderly (Hatakka, 2007). Based on 
our previous experience in clinical trials in measuring gastrointestinal symptoms 
in children, (Hatakka et al., 2007; Hatakka et al., 2001), adults (Kajander et al., 2005; 
Myllyluoma et al., 2005) and the elderly (Hatakka, 2007), we used the same methodology 
also in the present study. 
To summarize, the selection of probiotic strains for clinical studies was 
based on systematical immunological screening in an extensively used 
PBMC model. The clinical interventions were performed in a randomized, 
double-blind, placebo-controlled manner, which is considered to be the 
golden standard for intervention trials. A broad range of well-established 
immunological measurements along with novel lipidomics technique were 
utilized to get a comprehensive picture on possible immunomodulatory 
eﬀ ects of probiotics.
– 88 –
6.2 Main ﬁ ndings
6.2.1 Production of cytokines in peripheral blood mononuclear 
cells in vitro 
Probiotic strains from six diﬀ erent genera were clearly diﬀ erent in their ability to induce 
cytokine responses in PBMC in vitro. All strains were able to induce TNF-α production, 
which is consistent with previous studies in human PBMC (Foligne et al., 2007; 
Gackowska et al., 2006; Miettinen et al., 1998; Miettinen et al., 1996; Niers et al., 2005; 
Shida et al., 2006a; Timmerman et al., 2007). Interestingly, Lactobacillus and Biﬁ dobacterium 
strains which have previously been shown to stimulate IL-12 and IFN-γ production in 
human PBMC (Haller et al., 2000; Hessle et al., 2000; Hessle et al., 1999; Miettinen et 
al., 1998; Niers et al., 2005), were found be relatively poor inducers of these cytokines 
by the present study. Instead, it was found that potentially probiotic S. thermophilus 
and Leuconostoc strains were extremely good inducers of the said Th1-type cytokines. 
Cytokine proﬁ les may provide mechanistic explanations for the observed clinical eﬀ ects. 
A strong Th1-type cytokine response promoting cell-mediated immunity and especially 
IFN-γ due to its anti-viral activity is important in the defence against viral infections. 
In allergic diseases, the immune response is skewed towards Th2-type responses and 
balancing the response towards Th1-type prominent responses would thus be helpful. 
Diﬀ erent Lactobacillus strains have previously been shown to prevent and ameliorate the 
symptoms of respiratory infections (de Vrese et al., 2005b; de Vrese et al., 2006; Hatakka 
et al., 2001; Turchet et al., 2003; Winkler et al., 2005). LGG has also been used successfully 
in the treatment of rotavirus diarrhoea (Isolauri et al., 1994; Majamaa et al., 1995; Pant 
et al., 2007) as well as in the prevention or treatment of atopic diseases (Isolauri et al., 
2000; Kalliomäki et al., 2001; Viljanen et al., 2005c). It is of interest that LGG has been 
eﬀ ective in diﬀ erent immune-mediated diseases even though in the present study LGG 
induced only moderate cytokine production compared to the other strains. This may be 
due to the fact that cytokine induction is only one of the proposed mechanisms of action 
of probiotics. The eﬀ ects of potentially probiotic S. thermophilus and Leuconostoc strains 
warrant further attention in the prevention of infections and allergy in clinical studies. 
In addition, other probiotic characteristics should be studied before these new strains 
can be called probiotics.
Biﬁ dobacterium and Propionibacterium strains induced the highest IL-10 and the 
lowest IL-12 production indicating high anti-inﬂ ammatory capacity. This observation 
is consistent with previous ﬁ ndings where biﬁ dobacteria were shown to induce higher 
IL-10 production as compared to lactobacilli (Helwig et al., 2006; Lammers et al., 2003; 
Timmerman et al., 2007). There is preliminary evidence that probiotics could be used 
in the treatment of inﬂ ammatory diseases, such as ulcerative colitis, pouchitis and 
rheumatoid arthritis (for review, see Jones and Foxx-Orenstein, 2007; Saxelin et al., 
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2005) and the amelioration of these inﬂ ammatory diseases could be due to the ability of 
probiotics to induce IL-10. Recent studies indicate a possible role of low-grade mucosal 
inﬂ ammation also in the pathogenesis of irritable bowel syndrome (Chadwick et al., 
2002; O'Mahony et al., 2005). Preliminary evidence indicating that a combination of 
probiotics, including anti-inﬂ ammatory Biﬁ dobacterium and Propionibacterium strains in 
addition to two diﬀ erent L. rhamnosus strains, relieves the symptoms of irritable bowel 
syndrome is available (Kajander et al., 2005; Kajander et al., 2008). Biﬁ dobacterium and 
Propionibacterium, able to induce anti-inﬂ ammatory IL-10 production in this study, could 
thus be used to treat diﬀ erent types of inﬂ ammatory diseases. 
The use of probiotic bacterial combinations in clinical trials has shown great 
promise highlighting the importance of understanding the immunological 
properties of a single strain versus diﬀ erent bacterial combinations (Kajander et al., 
2005; Kukkonen et al., 2007; Myllyluoma et al., 2005). However, there is virtually no 
comparative data on the immunomodulatory properties of probiotic multispecies 
within the same experimental system (Castellazzi et al., 2007; Drouault-Holowacz et al., 
2006). Published data is generally limited to the comparisons of probiotic monostrains 
of the Lactobacillus and Biﬁ dobacterium genera (Foligne et al., 2007; Helwig et al., 2006; 
Miettinen et al., 1998; Timmerman et al., 2007). In the present study, combinations of 
diﬀ erent Gram-positive probiotic bacteria did not induce any additive or synergistic 
cytokine production in PBMCs and the responses were an average of the responses 
of the individual strains. This could be due to the fact that all Gram-positive bacteria 
are likely to use the same or similar intracellular signal transduction mechanisms to 
induce cytokine gene expression. Gram-positive bacteria or their structural components 
activate host cells via TLR2, whereas Gram-negative bacteria and their major structural 
component lipopolysaccharide activate host cells via TLR4 (Akira, 2001). It is, however, 
likely that other receptor systems apart from TLRs take part in host cell responses to 
diﬀ erent microbes (Robinson et al., 2006). Diﬀ erent bacteria seem to compete with 
each other during bacteria-host cell interactions. 
In summary, probiotics diﬀ er in their ability to induce cytokine responses. 
The Biﬁ dobacterium and Propionibacterium strains possessed the best anti-
inﬂ ammatory potential while the Streptococcus and Leuconostoc strains 
were good inducers of Th1-type cytokines in PBMC model. Screening of the 
immunomodulatory properties of probiotics can help in selecting strains for 
clinical trials for diﬀ erent purposes. Eﬀ ects of probiotic multispecies should be 
studied as their responses diﬀ er from the probiotic monostrains.
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6.2.2 Immunomodulatory eﬀ ects of probiotics in healthy adults 
Monocytes, IL-6 and CRP
This is the ﬁ rst study to show that LGG may result in reduced serum highly sensitive CRP 
levels even in healthy adults. Previously, the eﬀ ect of probiotics on CRP has only been 
studied in diﬀ erent disease conditions. A combination of L. casei, B. breve and prebiotic 
galactooligosaccharides (Sugawara et al., 2006) and B. longum (Furrie et al., 2005) have 
reduced serum CRP levels in immunocompromised patients and also improved the 
overall clinical appearance of chronic inﬂ ammation (Furrie et al., 2005). In contrast to 
the studies above and to results of the present study, LGG increased serum sensitive CRP 
levels compared to placebo in infants with IgE-associated atopic eczema (Viljanen et al., 
2005b). However, LGG had no eﬀ ect on serum CRP levels in patients with rheumatoid 
arthritis (Hatakka et al., 2003). It is of interest that a combination of four probiotic 
bacteria (LGG, Lc705, Bb99, PJS) had no eﬀ ect on sensitive CRP (Viljanen et al., 2005b) 
in the same clinical setting with allergic children. In immunocompromised patients 
undergoing surgical procedures, L. plantarum 299V (McNaught et al., 2005; McNaught 
et al., 2002) or a combination of L. acidophilus La5, Bb12, S. thermophilus and L. bulgaricus 
(Anderson et al., 2004; Reddy et al., 2007) did not change serum CRP concentrations, 
either. The eﬀ ect of probiotics on CRP appears controversial and the comparison of 
eﬀ ects is rendered diﬃ  cult by the diﬀ erences in the measurement technique (highly 
sensitive vs. normal CRP measurement), the diﬀ erent patient materials (healthy vs. 
various diseases) and the diﬀ erent probiotic strains that have been used. It seems that 
age, the individual immunological status and the probiotic strain used in the study 
have a great impact on the immunomodulatory eﬀ ects. The present ﬁ nding on CRP 
lowering eﬀ ect warrants further research, also during inﬂ ammatory processes and in 
individuals suﬀ ering from various types of inﬂ ammatory or autoimmune diseases. 
In addition to a lowered sensitive CRP level, the number of circulating monocytes 
and the serum IL-6 concentration was lower in the LGG group. IL-6 is produced 
by monocytes and it plays a key role in acute-phase responses (Bruunsgaard, 2005; 
Gabay, 2006). IL-6 is an important mediator of inﬂ ammation, being able to induce 
the production of CRP, as well as a sensitive marker of inﬂ ammation produced by 
hepatocytes and other acute-phase proteins and inﬂ ammatory factors (Kishimoto, 
2006; Volanakis, 2001). The ﬁ nding of the present study that LGG reduced serum 
IL-6 levels is supported by another study in healthy adults showing a decrease in IL-6 
production in peripheral blood mononuclear cells after LGG consumption (Schultz et 
al., 2003). Furthermore, another Lactobacillus strain, L. plantarum 299v has also reduced 
serum IL-6 levels in critically ill patients (McNaught et al., 2005) and in heavy smokers 
(Naruszewicz et al., 2002). 
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Production of cytokines by peripheral blood mononuclear cells ex vivo
LGG reduced Gram-positive pathogen-induced TNF-α responses in the ex vivo cultured 
PBMC. TNF-α is secreted by the monocytes, and it acts as an inﬂ ammatory mediator 
activating many types of cells. The present ﬁ nding is supported by another clinical 
study carried out in healthy adults, showing that LGG treatment leads to decreased 
TNF-α production in PBMC (Schultz et al., 2003). In addition, when the cytokine 
expression pattern in the small bowel mucosa of healthy adults was studied, it was 
found that LGG induced the expression of genes involved in immune response and 
inﬂ ammation (TGF-beta and TNF family members, cytokines, nitric oxide synthase 
1, defensin alpha 1) (Di Caro et al., 2005). LGG appears to modulate PBMC responses 
diﬀ erently in healthy and allergic individuals as LGG increased the Th1-type cytokine 
IFN-γ production in PBMC in allergic infants (Pohjavuori et al., 2004).
Additionally, Bb12 was found by the present study to decrease IL-2 production in 
inﬂ uenza virus-stimulated PBMC, indicating an anti-inﬂ ammatory eﬀ ect. This ﬁ nding 
is new, as a combination of Bb12 and L. paracasei ssp. paracasei CRL-431 had no eﬀ ect 
in ex vivo-stimulated blood cytokine production in healthy adults (Christensen et al., 
2006). Activating NK cells and inducing activation and proliferation of T lymphocytes, 
IL-2 is a very important cytokine in viral infections and inﬂ ammatory responses. 
Therefore, IL-2 production might be an important factor for a probiotic ﬁ ghting 
against respiratory tract infections. Based on the present results, the Biﬁ dobacterium 
strain might not be the most optimal strain against respiratory infections. Indeed, it 
is mainly probiotic strains from the Lactobacillus genera — L. rhamnosus GG (Hatakka 
et al., 2001), L. casei DN-114001 (Turchet et al., 2003), a combination of L. gasseri PA 16/8, 
B. longum SP 07/3 and B. biﬁ dum MF 20/5 (de Vrese et al., 2005b; Winkler et al., 2005), 
and L. reuteri (Tubelius et al., 2005) — that have reduced the incidence or symptoms of 
respiratory infections. 
To summarize, probiotics are able to induce strain-speciﬁ c 
immunomodulatory eﬀ ects that are reﬂ ected even to the systemic level and 
that may possess an anti-inﬂ ammatory potential in healthy individuals. 
LGG appears to reduce inﬂ ammatory mediators, such as sensitive CRP and 
IL-6. LGG and Bb12 seem to have a role in modulating the functional responses 
of PBMC. 
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6.2.3 Global serum lipidomics proﬁ ling 
This study is the ﬁ rst to apply lipidomics technique to analyze global lipidomics 
proﬁ les in healthy individuals after a probiotic intervention. Lipid-derived 
compounds are important mediators of inﬂ ammation. LGG intervention seemed to 
cause changes in global lipidomic proﬁ les reﬂ ected as decreased proinﬂ ammatory 
lysophosphatidylcholines and sphingomyelins and elevated triacylglycerols and 
glycerophosphocholines. Sphingomyelins are known to be involved in the immune 
cell function as well as in the regulation of inﬂ ammation (Melendez, 2008; Olivera 
and Rivera, 2005; Won and Singh, 2006). Previously, lysophosphatidylcholines have 
induced an increase in several inﬂ ammatory cytokines (IL-1β, IL-6, TNF-α) in 
human PBMC (Shi et al., 2007). The reductions observed in the present study in both 
proinﬂ ammatory lysophosphatidylcholines and sphingomyelins may thus be related 
to the observed anti-inﬂ ammatory actions of LGG in general. High concentrations of 
both lysophosphatidylcholines (Haapamäki et al., 1999; Minami et al., 1994) and lipids 
of the sphingomyelin/ceramide pathway (Homaidan et al., 2002; Sakata et al., 2007) 
have been associated with inﬂ ammatory bowel disease as well as impaired mucosal 
barrier function and increased gut permeability (Karlqvist et al., 1986; Otamiri et al., 
1986; Sawai et al., 2002; Tagesson et al., 1985). Interestingly, previous studies have shown 
LGG to maintain the remission in patients with ulcerative colitis (Zocco et al., 2006) as 
well as to normalize gut permeability (Isolauri et al., 1993b) and enhance the mucosal 
integrity and epithelial cell survival (Lam et al., 2007; Yan et al., 2007). 
In summary, novel global lipidomics proﬁ ling revealed a tendency towards 
decreased proinﬂ ammatory lysophosphatidylcholines and sphingomyelins after 
LGG intervention which might be related to the observed anti-inﬂ ammatory 
eﬀ ects of LGG in general.
6.2.4 Clinical outcome
Prevention of respiratory infections
The eﬀ ect of LGG on respiratory infections has not been studied in adults before. In the 
present study, LGG did not reduce the incidence or duration of respiratory infections in 
healthy adults training for a marathon, although the number of healthy days during the 
intervention was slightly, but not signiﬁ cantly, higher in the LGG group. On the contrary 
to the present study, LGG reduced respiratory infections and the absence from day-care 
due to illness in healthy day-care children (Hatakka et al., 2001) and a combination of 
LGG, Lc705, Bb99 and PJS reduced the occurrence of recurrent respiratory infections 
in otitis-prone children (Hatakka, 2007). It may be that the eﬀ ect of LGG on respiratory 
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infections is diﬀ erent in adults and children. Again, contrary to the present study, 
L. fermentum VRI 003 reduced the number of days with respiratory symptoms in elite 
distance runners (Cox et al., 2008). In contrast, L. casei DN114001 had no eﬀ ect on the 
incidence or symptoms of respiratory infections in healthy men in French Commando 
training (Tiollier et al., 2007). It is possible that the level of training in the present study 
and in the study by Tiollier et al. (2007) was not high enough to depress the immune 
system as compared with elite distance runners investigated in the study by Cox et al. 
(2008). In addition, previous studies in children (Cobo Sanz et al., 2006; Hatakka et al., 
2007; Hatakka et al., 2001; Weizman et al., 2005), adults (de Vrese et al., 2005b; de Vrese et 
al., 2006; Winkler et al., 2005) and the elderly (Hatakka, 2007; Turchet et al., 2003) have been 
carried out in wintertime whereas the present study was performed during the summer 
months due to the marathon race. It may be that the study being performed at summer 
and the number of subjects being relatively small compared with previous studies (141 
vs. 200-500) counteracted the minor beneﬁ cial eﬀ ects of LGG on the measured variables 
in healthy adults. 
Prevention of gastrointestinal symptoms
The eﬀ ect of probiotics on community-acquired diarrhoea or gastrointestinal 
symptoms has not received much attention although LGG as well as other probiotics 
have been eﬀ ective in prevention and treatment of acute infectious diarrhoea, 
travellers’ diarrhoea and antibiotic-associated diarrhoea (for review, see Sazawal et al., 
2006). In the present study, LGG shortened the duration of gastrointestinal symptom 
episodes (including diarrhoea, vomiting and/or stomach ache) in more than half of 
the healthy adults training for a marathon. This ﬁ nding is in accordance to previous 
studies, although they were conducted in the elderly (Turchet et al., 2003) and in 
children (Chouraqui et al., 2004; Pedone et al., 1999; Weizman et al., 2005). A reduction 
in the duration of gastrointestinal symptoms may be especially signiﬁ cant for athletes, 
such as long distance runners, because they are known to suﬀ er from gastrointestinal 
disturbances (for review, see Riddoch and Trinick, 1988; Simons and Kennedy, 2004). 
Furthermore, long-distance running is known to aﬀ ect the integrity of the gastric and 
intestinal mucosa and to increase gut permeability (Oktedalen et al., 1992; Smetanka et 
al., 1999). There are also indications that LGG could have beneﬁ cial eﬀ ects on mucosal 
permeability in animal (Isolauri et al., 1993a; Isolauri et al., 1993b; Pessi et al., 1998) and 
in clinical studies (Gotteland et al., 2001). The eﬀ ect of LGG on the gut barrier function 
should be evaluated in further studies.
Interestingly, subjects in the LGG group reported to exercise signiﬁ cantly more 
often per week than the placebo group during the three-month period before the 
marathon even though the randomization to groups was done according to the level 
of exercise. The higher rate of exercise in the LGG group may be related to the higher, 
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although insigniﬁ cant, number of healthy days without gastrointestinal symptoms or 
symptoms of respiratory infections. The higher rate of exercise in the LGG group may 
also be reﬂ ected in the higher cortisol level as a marker of exercise-induced stress at 
the end of the intervention, although the other measured hormones, prolactin and 
testosterone, were at a comparable level in both groups. 
In summary, LGG had no eﬀ ect on the incidence or duration of respiratory 
infections, but it was able to shorten the duration of gastrointestinal symptoms 
in healthy exercising adults.
6.2.5 Relationship between in vitro, ex vivo and in vivo results
In the primary cell culture study model using PBMC, the most potential anti-
inﬂ ammatory probiotics were Biﬁ dobacterium and Propionibacterium strains based on 
their ability to induce high IL-10 (anti-inﬂ ammatory cytokine) and low IL-12 (Th1-
type cytokine) production. In addition, LGG was selected for further studies as a well-
documented probiotic even though it was not particularly active in inducing cytokine 
responses. The results of the in vivo setting did not reﬂ ect the in vitro results. In the 
clinical intervention study, the best anti-inﬂ ammatory strain was LGG, which induced 
very moderate IL-10 production in vitro compared with Bb12 and PJS strains. In the 
clinical setting, LGG had the most promising anti-inﬂ ammatory eﬀ ects as the sensitive 
CRP level and TNF-α produced by PBMC ex vivo were at the lowest level during the 
LGG intervention. Also Bb12 and PJS exerted some anti-inﬂ ammatory activity in vivo, 
as IL-2 levels produced by PBMC ex vivo were lower in the Bb12 group than in other 
groups during the intervention and the CRP levels were at comparable levels with the 
LGG group and the PJS group. At present, attempts to compare the in vitro results of one 
probiotic to its results in an in vivo setting are limited to comparisons between in vitro 
and experimental animal studies. In these studies, the anti-inﬂ ammatory eﬀ ects seen as 
a high IL-10/IL-12 ratio in vitro have been reﬂ ected as protective eﬀ ects in TNBS colitis 
model in vivo (Drouault-Holowacz et al., 2006; Foligne et al., 2007) and the modiﬁ cation 
of the cytokine response towards Th1-type response in vitro has been reﬂ ected as 
prevention of allergic response in vivo (Hisbergues et al., 2007). Furthermore, this 
study showed no correlation between serum cytokine levels and cytokines produced 
by PBMC ex vivo. Moreover, most of the changes were observed in the ex vivo produced 
cytokines. This raises the question on the relevance of serum cytokine measurements 
in probiotic interventions, especially in healthy adults.
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Taken together, screening of the immunomodulatory properties of probiotics 
in vitro did not reﬂ ect the eﬀ ects in vivo. The PBMC in vitro should not be 
used as the only screening method for immunomodulatory properties of 
probiotics. However, the ex vivo production of cytokines after probiotic 
intervention could oﬀ er a relatively easy and quick method for screening of 
immunomodulatory eﬀ ects. 
6.3 Clinical relevance and future aspects
All subjects investigated in the present study were healthy adults. The study covered a 
range of measurements of immunomodulation and inﬂ ammatory mediators as well 
as respiratory infections and gastrointestinal symptoms as clinical outcomes. Several 
small decreases in the inﬂ ammatory mediators (sensitive CRP, serum IL-6, TNF-α 
and IL-2 produced by PBMC ex vivo, sphingomyelin, lysophosphatidylcholine) were 
observed, indicating anti-inﬂ ammatory potential of probiotics. The clinical relevance 
of inﬂ ammatory mediators in healthy individuals and the relevance of observed small 
changes within a normal range, if established, can be questioned. It is clearly evident 
that a small change in one measurement does not necessarily denote better defence 
against inﬂ ammatory agents or infection. However, if small changes can be observed in 
several measurements and especially if the markers are clearly linked with each other, 
this gives indications of biologically meaningful events. The real impact of probiotics 
as anti-inﬂ ammatory substances thus warrants further research during inﬂ ammatory 
processes and in individuals suﬀ ering from various types of inﬂ ammatory diseases. For 
future probiotic interventions, screening of subjects for imbalance in inﬂ ammatory 
mediators would be advisable, even in apparently healthy adults. Additionally, the 
shortening of the duration of gastrointestinal symptoms with more than half after 
probiotic intervention can be considered as clinically meaningful. As the actions of 
probiotics are most probably mediated via the gut mucosal immune system, it would 
be extremely important to clarify the actual events in the gut mucosa. Lipidomics and 
other approaches of systems biology, such as gene expression analysis, proteomics and 
metabolomics, may provide powerful means for identifying new biomarkers behind the 
clinical eﬀ ects of diﬀ erent nutritional interventions. They may also better characterize 
the clusters of small changes in markers associated with one other as they are able to 
detect changes in numerous markers from various sample materials simultaneously. 
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7. Summary and conclusions
The present study investigated the immunomodulatory eﬀ ects of probiotics in 
a primary cell culture model using human PBMC as well as in healthy adults 
in randomized, double-blind, placebo-controlled clinical intervention studies. 
The main ﬁ ndings in the present study were as follows:
1.  Probiotic strains from six diﬀ erent genera showed clear diﬀ erences in their ability 
to induce cytokine responses in PBMC in vitro. Strains belonging to the Streptococcus 
and Leuconostoc genera were the most potent inducers of Th1-type cytokines, 
whereas strains from the Biﬁ dobacterium and Propionibacterium genera induced 
anti-inﬂ ammatory IL-10 production. No combinations of probiotics resulted in 
enhanced cytokine production suggesting that diﬀ erent bacteria compete with each 
other during host cell-probiotic interactions. 
2.  Probiotics, especially LGG, appeared to have anti-inﬂ ammatory eﬀ ects in healthy 
adults reﬂ ected as a small decrease in inﬂ ammatory mediators, such as sensitive 
CRP, inﬂ ammatory cytokines as well as inﬂ ammatory lipid-derived mediators, 
namely lysophosphatidylcholines and sphingomyelins, in serum. Both LGG and 
Bb12 seem to have a role in modulating the functional responses of PBMC. 
3.  The in vitro screening of cytokine responses in a primary cell culture using human 
PBMC should not be used as the only indicator of immunomodulatory properties 
of probiotics, as the in vitro model did not reﬂ ect the eﬀ ects in vivo. Instead, the 
ex vivo production of cytokines in PBMC after probiotic intervention could oﬀ er 
a relatively easy and quick model for screening of immunomodulatory eﬀ ects of 
probiotics. Calculations of the ratios between pro- and anti-inﬂ ammatory or Th1/Th2 
cytokines could give useful information on the speciﬁ c properties of probiotics. 
4.  LGG had no eﬀ ect on the incidence or duration of respiratory infections in 
healthy adults. However, LGG was able to reduce the duration of gastrointestinal 
symptoms. 
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In conclusion, probiotics are strain-speciﬁ cally able to modulate the release and 
actions of inﬂ ammatory mediators in healthy adults. Immunomodulatory eﬀ ects of 
probiotic multispecies should be studied as the eﬀ ects diﬀ er from single strains. The 
ex vivo production of cytokines in PBMC after probiotic intervention could be used 
as a screening method for immunomodulatory properties of probiotics. New cutting-
edge systems biology technologies may provide new tools for further investigation of 
the mechanisms of speciﬁ c host-probiotic interactions in the gut resulting in systemic 
and clinical eﬀ ects. 
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